CA1339953C - 2',5'-phosphorothioate oligoadenylates and antiviral uses thereof - Google Patents

2',5'-phosphorothioate oligoadenylates and antiviral uses thereof

Info

Publication number
CA1339953C
CA1339953C CA000580426A CA580426A CA1339953C CA 1339953 C CA1339953 C CA 1339953C CA 000580426 A CA000580426 A CA 000580426A CA 580426 A CA580426 A CA 580426A CA 1339953 C CA1339953 C CA 1339953C
Authority
CA
Canada
Prior art keywords
thioadenylyl
compound
adenosine
phosphorothioate
monophosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000580426A
Other languages
French (fr)
Inventor
Robert J. Suhadolnik
Wolfgang Pfleiderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Application granted granted Critical
Publication of CA1339953C publication Critical patent/CA1339953C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Abstract

Optically active compounds of the formula

Description

2',5'-PHOSPHOROTHIOATE OLIGOADENYLATES
AND ANTIVIRAL USES TH~REOF
Field of the Invention The invention relates to synthetic analogues of naturally occurring antiviral 2l,5'-oligoadenylates wherein the internucleotide phosphodiester linkages are replaced with optically active phosphorothioate groups. The compounds have increased metabolic stability where the stereoconfiguration around one or more of the chiral - 10 phosphorous atoms is the Sp configuration.
Reference to Government Grant The invention described herein was made, in part, in the course of work supported by National Institutes of Health grant POl CA-29545 and National Science Foundation grant DMB84-15002.
Background of the Invention The full nomenclature of the subject matter of the present invention involves extremely long terms. It is customary for those skilled in the art to abbreviate oligoadenylate analogues and related terms in a manner well-known to them. These general and customary abbreviations are set forth herein below and may be utilized in the text of this specification.

-2- 1 3 ;~ ) 3 Abbreviations:
2-5A, 2',5'-oligoadenylate or p3An Oligomer of adenylic acid with 2',5'-phosphodiester linkages and a 5'-terminal triphosphate group.
A2, A3 and A4: Dimer, trimer and tetramer of adenylic acid with 2',5'-phosphodiester linkages.
pA3~ ppA3 (or p2A3), pppA3 (or p3A3): 5'-terminal mono-, di- and triphosphates of A3 AMPS: Adenosine 5'-O-phosphorothioate.
SVPD: Snake venom phosphodiesterase.
2'-PDE: 2'-phosphodiesterase Rp: The R stereoconfiguration about a chiral phosphorous atom in a phosphorothioate internucleotide linkage.
Sp: The _ stereoconfiguration about a chiral phosphorous atom in a phosphorothioate internucleotide - linkage.
RNase L: 2-5A dependent endoribonuclease.
ARpARpA: (Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine.
ASpARpA: (Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-~2'-5')-adenosine.
ARpASpA (Rp)-P-thioadenylyl-(2'-5')-(_p)-P-thioadenylyl-(2'-5')-adenosine.
ASpAspA: (_p)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
PARpARpA~ PpARpARpA~ pppARpARpA~ pASpARpA~ pPASPARP
pPPASpARpA, pARpASpA ~ ppARpAspA, pppARpAspA, pAsp ppAspAspA~ and pppAspAspA: 5'-mono-, di- and triphosphates of ARpARpA~ ASpARpA~ ARpASpA and ASpAspA.
-3- 133~ ~3 ARpARpARpA: ( Rp) -P-thioadenylyl-(2'-5' )-(Rp)-P-thioadenylyl-( 2 ' -5 ' )-( Rp)-P-thioadenylyl-(2' -5' )-ade nos i ne .
A Rp AS p A Rp A : ( Rp ) - P - t h i o a d e n y l y l - ( 2 ' - 5 ' ) ~ P-th ioadenyl yl - ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenos ine .
A Rp A Rp A S p A : ( P~p ) - P - t h i o a d e ny 1 y 1 - ~ 2 ' - 5 ' ) - ( Rp ) - P -th ioadeny ly 1- ( 2 ' -5 ' ) - ( _p ) -P-th ioadenylyl- ( 2 ' -5 ' ) -adenos i ne .
ARpASpAspA: (Rp)-P-thioadenylyl-(2'-5')-(_p)-P-thioadenylyl-(2' -5' )-(Sp)-P-thioadenylyl-(2'-5' )--ade nos i ne .
ASpARpARpA: ( Sp ) -P-th ioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenosine .
ASpASpARpA: (_p)-P-thioadenylyl-(2'-5~ )-(_p)-p-thioadenylyl-(2'-5' )-(_p)-P-thioadenylyl-(2~-5~ )-adenosine.
ASpARpAspA: ( Sp ) -P-th ioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl-(2'-5' )-(Sp)-P-thioadenylyl-(2'-5' )-adenosine.
ASpASpASpA: (_p)-P-thioadenylyl-(2'-5~ )-(_p) th ioadenylyl- ( 2 ' -5 ' ) - ( Sp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenosi ne .
pARpARpARpA, ppARpARpARpA, pppARpARpARpA, pARpAspARpA~ ppARpAspARpA~ pPPARpAspARpA~ pARpARpASPA' ppARpARpAspA, pppARpARpAspA ~ pARpAspAspA ~ ppARpASpASp PPPARpASpASpA~ pASpARpARpA~ ppAspARpARpA~ pppAspARpARpA~
PASpASpARpA ~ pPASpASpARpA ~ pppAspAspARpA~ pAspARpAspA~
ppAspARpAspA~ pppAspARpAspA~ pAspAspAspA~ pPASpASpASpA' pppAspAspAspA: 5 ' -mono-, di- and triphosphates of the above tetramers .
(_p) - ATP-alpha-S: Adenosine 5'0-(Sp)-(l-th i ot r iph ospha te ) .
Background of the Invent ion The 2-5A system is widely expected to be involved in the antiviral mechanism of interferon and may also be 1 ~ '3 '~ 9 ~-~ 3 involved in the regulation of cell growth and differentiation. 2-5A synthesized from ATP by 2',5'-oligoadenylate synthetase [ATP: (2'-5')oligo(A)-adenyltransferase (EC 2.7.7.19)1 exerts its biological effects by binding to and activating its only known target enzyme, the unique 2-5A-dependent endoribonuclease RNase L
(EC 3.1.27). RNase L cleaves viral and cellular m~NA or rRNA, thereby inhibiting protein synthesis. Hovanessian et al, ~ur. J. Biochem. 93:515-526 (1979); Kerr et al, Proc.
Natl. Acad. Sci. USA. 75:256-260 (1978). It has been reported that 2-5A protects plant tissue from infection by tobacco mosaic virus. Devash et al, Science 216:415 (1982). 2-5A, however, is metabolically unstable. It is degraded by a cellular 2'-phosphodiesterase and phosphatases. Knight et al, Meth. Enzymol. 79:216-227 (1981); Minks et al, Nucleic Acids Res. 6:767-780 (1979);
Williams et al, Eur. J. Biochem. 92:455-462 (1978).
The literature is replete with structurally-modified 2-5A molecules with modifications in the adenyl or ribosyl moiety designed to explore the biological role of the 2-5A
synthetase/RNase L system. The primary source of conformational flexibility in the 2-5A molecule is in the backbone, similar to 3',5'-linked RNA and DNA. Srinivasan et al, Nucleic Acids Res. 13:5707-5716 (1985). However, theoretical and experimental analyses have revealed that the conformation of 2', 5'-linked dinucleotides and polynucleotide chains are significantly different from 3',5'-linked nucleotides. Id. The ribose-phosphate backbone of 2-5A has also been demonstrated to be the major antigenic determinant in the molecule. Johnston et al, Biochemistry 22:3453-3460 (1983).
Few reports have appeared on the synthesis of 2-5A
analogues with backbone m-odifications. Core analogues containing methylphosphonate and methylphosphotriester 13~9 73~ 3 groups have been synthesized. Eppstein et al, J. Biol.
Chem. 257:13390-13397 (1982); Jager et al, Nucleic Acids Res. Sym. Ser. No. 9:l49-152 (1981). However, complete loss of activity was observed with the "uncharged"
methylphosphotriester analogues. Eppstein et al, supra.
Substitution of the 2',5'-phosphodiester linkages with 3', 5'-linkages has also lead to substantial decrease in biological activity. Lesiak et al, J. Biol. Chem.
258:13082-13088 (1983). Replacement of only one 2',5'-internucleotide linkage has resulted in at least one order of magnitude loss of activity. Nearly complete loss of biological activity was observed when both 2',5'-phosphodiester linkages in the 2-5A trimer were replaced with 3',5'-bonds.
Haugh et al, Eur. J. Biochem. 132:77-84 (1983), reported that the affinity of pA3 to RNase L in mouse L929 cell extracts is approximately 1,000 times greater than that of A3.
Nelson et al, J. Org. Chem. 49:2314-2317 (1984), describe diastereomeric pairs of the phosphorothioate analogue of A3 without resolution of individual enantiomers. Eppstein et al, J. Biol. Chem. 261:5999-6003 (1986) report metabolic stabilities and antiviral activity of purported ARpARpA/ASpARpA and ARpASpA/AspAspA racemic mixtures without resolution of individual enantiomers.
Lee and Suhadolnik, Biochemistry 24:551-555 (1985), and Suhadolnik and Lee in The 2-5A System: Holecular and Clinical Aspects of the Interferon-Regulator Pathway, Williams, B.R.G. and Silverman, R.H., Eds. (1985), Alan R.
Liss, Inc., New York, p. 115-122, disclose the enzymatic synthesis of the alpha-phosphorothioate 5'-triphosphates of ARpARpA and ARpARpARpA from (_p)-ATP-alpha-S Such compounds are metabolically unstable. Preparation of the corresponding stereoisomers with Sp internucleotide -6- 1~3~ 3 phosphorothioate linkages was not possible owing to the stereospecificity of 2-5A synthetase for the substrate (Sp)-ATP-alpha-S, which is inverted to yield trimer and tetramer products containing 2',5'-phosphorothioate internucleotide linkages of the P~p configuration exclusively. Because nucleoside tranferases provide exclusively the inverted configuration when ~p-ATP-alpha-S
is the substrate, 2',5'-phosphorothioate oligoadenylates containing internucleotide phosphorothioate groups of the Sp configuration cannot be synthesized enzymatically.
Summary of the Invention Compounds of the present invention useful in inhibiting viral infections in plants and mammals have increased metabolic stability and/or antiviral activity.
The compounds are optical isomers and water-soluble salts thereof of the formula NHz HO p-O--C~
~,:

~o NHz -O- '=S N~N
C~N NJ

HO OH

substantially free of contamination by other optical isomers of the same formula, wherein m is zero, 1,2 or 3; n is 1 or 2; and at least one of the internucleotide phosphorothioate groups r -7- 13399 '~

I

is of the Sp configuration.
The invention also comprises a method of inhibiting viral infection in mammals or plants by administering an antiviral effective amount of a compound according to the above formula, or a water-soluble salt thereof, and antiviral compositions containing such compounds with a carrier.
Compounds according to the formula wherein n is 2 may be utilized to form oligoadenylate conjugates with the macromolecular carrier poly(L-lysine) for intracellular transport. Such poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates have the formula l H2 l H2 ( ICH2)4 ( ~CH2)4 NH2CHCO~Rq~NHCHCOOH

wherein q is an integer from about 60 to about 70, and R is randomly R' or (ICH2)4 -NHCHCO-.

From about five to about ten of the R ~rou~s comprise R'.
R' has the following formula wherein m is 0,1,2 or 3:

~33~13 i3 HO--p-O--CH2 N~NJ
o L--~~.l ~ml~j HO

~- ,=5 N ~NZ
~ <~N ~NJ

HO ¦
1 0 ~~ N H2 -O-P=S N~N

HO
-~- '=S NH2 CH ~N~J
,~

t CH2 )~
--NH-CH-CO--Preferably, at least one of the phosphorothioate groups o -O- P=S
o of the poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates is of the Sp configuration.

605~-58 1~3~
g Description of the Figures Figure lA represents the results of a radiobinding assay indicating the ability of 2',5'-phosphorothioate adenylate trimer cores and 5'-monophosphates to compete with p3A4[32PlpCp for binding to the RNase L in L929 cell extracts. Approximately 60% of the probe was bound in the absence of added oligonucleotide (total dpm = 23,000). The curves are labelled as follows: A3 (o); p3A3 (x); pA3 (-);
ARpARpA (~); ASpARpA (O); ARpASpA (~); ASpAsp (O); pARpARp (~); pASpARpA (~); pARpAspA (~); pASpAspA (J).
Figure lB represents the results of a core-cellulose assay indicating the ability of the 2',5'-phosphorothioate adenylate trimer cores and 5'-monophosphates to activate partially-purified RNase L from L929 cell extracts to hydrolyze the substrate poly(U)-3'-[32P3pCp. Activation of RNase L was determined by conversion of poly(U)-3'-[32P]pCp to acid-soluble fragments. 100% represents 30,000 cpm of labelled poly(U)-3'-[32P]pCp bound to glass fiber filters. The curves are labelled in the same manner as Figure lA.
Detailed Description of the Invention The activation of the unique 2-5A-dependent endoribonuclease, RNase L, by 2',5'-oligoadenylates, and its hydrolysis of rRNA, tRNA and cellular and viral mRNA, is important in the inhibition of viral replication and regulation of cell growth. RNase L is known to be the substrate target for 2-5A. It is one of the chief functional enzymes of the interferon-induced biological cascade. While modified analogues of 2-5A have been reported, they are not metabolically stable, or fail to activate RNase L. The introduction of the phosphorothioate group in the 2',5'-internucleotide linkages of 2-5A, induces physical, chemical and biochemical modifications in the 2-5A molecule including (i) Rp/Sp chirality, (ii) -lO- 133~ 3 lowered pKa, (iii) altered metal ion chelation, (iv) charge modulation, (v) increased bond length, (vi) altered degree of hydration and (vii) increased metabolic stabilities.
The metabolic stability of the 2',5'-phosphorothioate oligoadenylates is greater than authentic 2-5A. This metabolic ~,tability is greatly enhanced where at least one of the internucleotide phosphorothioate 2',5'-linkages is of the Sp configuration. While racemic mixtures of the trimer cores have been reported, Nelson et al, J. Org. Chem. 49:2314-2317 (1984) and Eppstein et al, J. Biol. Chem 261:5999-6003 (1986), efforts to resolve the compounds have failed. The level of antiviral activity of the trimer core racemates reported by Eppstein et al is such that the dosages required ~or treatment would be prohibitively toxic. At least one of the purported racemates of Eppstein et al, the ARpASpA/AspAspA racemate, is of little value since, as we have found, the ASpAspA
stereoisomer selectively inactivates RNase L, thereby preventing ARpASpA from exerting its antiviral effect through activation of RNase L. This is most undesirable since, as we have found, ARpASpA is the most attractive of the four trimer core stereoisomers, since it both activates RNase L and is metabolicly stable.
We have succeeded in preparing the fully resolved 2',5'-phosphorothioate adenylate trimer cores, thus making possible the practical use of the important ARpASpA
stereoisomer. Our method of stereo-specific chemical synthesis also makes possible the preparation of the eight separate stereoisomers of the 2',5'-phosphorothioate tetramer. Preparation of the tetramer molecules enables conjugation with the carrier (poly)L-lysine, shown to be an effective vector for introducing 2',5'-oligoadenylates and analogues into intact cells. Poly(L-lysine) conjugation to trimer molecules is not feasible, owing to the destruction -11- 1339l~-j3 of the 2'-terminal ribosyl moiety and subsequent i nact ivat ion of the molecu le . Con jugat ion to poly ( L-lysine) permits efficient intracellular transport of the 2' ,5'-phosphorothioate oligoadenylates while preserving intact within the con jugate the trimer moiety believed necessary for good biological activity.
Correlation of biological properties with absolute configuration has only been possible with the preparation of the fully resolved 2 ',5 ' -phosphorothioate adenylate trimer cores described herein. However, the trimer core compounds have been found to bind and/or activate RNase L
only modestly. We have found that the RNase L activation by the 2 ',5 ' -phosphorothioate core molecules is significantly enhanced by 5 ' -phosphorylation.
P~ase L activation by authentic 2-SA requires the triphosphate form of the trimer . The 5 ' -monophosphate form of 2-5A is a potent inhibitor of the RNase L-activating activity of the triphosphate. Miyamoto et al., J. Biol.
Chem 258: 15232-15237 (1983) i Black et al., FEBS Let.
191: 154 - 158 (1985); Torrence et al., Proc. Natl. Acad. Sci.
USA 78: 5993-5997 (1981) . We have surprisingly found that the cores and monophosphates of the present phosphorothioate analogues of 2-5A, unlike authentic 2-5A, activate RNase L.
The phosphorothioate trimer cores ARpARpA, ASpARpA, ARpASpA, and ASpAspA, are chemically synthesized and separated by preparative thin layer chromatography on silica gel . The four t rimer cores are prepared from 6-N-benzoyl- 3 ' -O-tert -butyld imethyls i lyl-5 ' -O-monomethoxytri tyladenos ine-2-O- (p-nitrophenylethyl )-octahydroazonino-phosphoramidite by stereospec i f ic synthesis, which relies on separation of fully resolved protected intermediates followed by removal of all blocking ~ ~ 3 ~3 1~ ~ 3 groups to yield the fully-resolved 2',5'-phosphorothioate trimer adenylate cores.
The trimer cores are prepared according to the following reactiorn scheme wherein "BZ" denotes the benzoyl radical ~Si" denotes the tert-butyldimethylsilyl radical and "MMTr" re~resents the monomethoxytrityl radical. While not part of the invention, the preparation of the dimer core enantiomers ARpA (6A) and ASpA (6B) is included for completeness.

-13- ~339~3 NH - C - C~,Hs N11B2 NHB2 CH30 ~C~O ~N 02N ~ CH2CH2 0 P - N~ s~ N
MMTrO~J HO~

CH3 - C - Si-O OH (~)O 1O ~) o O(~) CH3 C~3 02N 1~ CH2CH20 - P -N ~

N8Z NHeZ

~N NHBZ
MMTrO ~ N> Mt1TrO

02N~CH2CH20-Pj ~~ 02N~o pO ;5 N
~00~ - y, ~A I ~B I (~)~ ~ (~) NHBZ NHBZ

~N NtlE~Z ~N
6 A -- HO ~ N~S~ \> ~ ~N>

02N ~ H2017 ~S ~ 02N~ CH2CH20 _ ~ S ~I
(~30 ~(~) ~0 0 -14- 13 3 ~ ~ ) 3 NHBZ ¦ ~1BZ

~[ N N11BZ ~N N-IBZ
MMTrl) ~ N~N~ ~ MMTrO ~ N
o N , NHBZ @)o S I Nt~Z
02N~ 0~,0 - ~ --~~ ~N

~ O .--~~J 02N ~ Ot2CH20 - P~ yy S (~)0 0~) - 5 @)0 0(~) ~A ~B

NHBZ I NHE~2 ~N NHBZ ~N MlBZ
NMMTrO ~ N~5~N~>

o2N~3 0~0 P~ ~ ~J N NHE~ZN O N ~ 0~ ~ ~ ~ ~ N NllBZN
(~)~ ~ )0 1 ~ ~
02N~ ~~20 ~~~5 N ~O N~ 0120'l2o ~!~5 ~N~'N

(~)0 0(~ ~)0 0(~) -15- 1339~-~3 The blocking groups are removed from the fully-protected intermediates 7A, 7B, 8A, and 8B to yield the corresponding fully resolved trimer cores ARpARpA (9A), ASpA~pA ( 9B), ARpASpA ( lOA) and ASpASpA ( lOB):

1 3 3 9 9 j rf3 ~N~N HO-C~Ng <N~N ~NX~N
O ~x~H~ H ~ Ng ~N~

HO ~' ~~ NH2 HO O~ ,O NH HO o 'OcH ~N~N'J ~ <N~N'; ~N~HO o~p--s HO OH HO OH HO OH, HO ON

RpRp -SpRp RpSp SpSp 1339~ ~3 The compounds of the invention are advantageously prepared as soluble salts of sodium, ammonium or potassium.
- The preparative scheme begins with 6-N-benzoyl-3 ' -0-tert-butyldimethylsilyl-5 '-0-monomethoxy-trityladenosine (compound lE), which is advantageously prepared from adenosine according to the procedure of Flockerzi et al, Liebigs Ann. Chem., 1568-1585 (1981) .
Preparation of the compounds of the present invention is illustrated in more detail by reference to the following non-limiting examples. 3-Nitro-1,2,4-triazole; chloro-octahydroazonino-p-nitrophenylethoxyphosphate; 2,5-dichlorophenylphosphoro-dichloridate; and p-nitrophenylethanol used in the examples may be prepared advantageously from published procedures: Chattopadhyaya et. al. Nucleic Acids Res. 8:2039-2053 (1980); Schwarz et al., Tetrahedron Lett. 5513-5516 (1984); Uhlmann et al., ~elv. Chim. Acta 64:1688-1703 (1981). These compounds are also available commercially in the United States. 2,5-Dichlorophenyl-phosphorodichloridate may be obtained from Fluka Chemical Corp., 980 S. Second St., Ronkonkoma, New York 11779, ( "Catalog 15: Chemika-Biochemika" 1986/1987, no. 36212). 3-Nitro-1,2,4-triazole is available from Aldrich Chemical Co., P.O. Box 355, Milwaukee , WI 53201 (1986-1987 cat. no. 24,179.2). P-Nitrophenylethanol is available from Fluka Chemical Corp. (cat. no. 73,610).
Chloro-octahydroazonino-p-ni trophenylethoxyphosphate may be prepared according to Example lA, below.
Pyridine and triet:hylamine used in the examples were purified by distillation over ~OH, tosyl chloride and calcium hydride. Dichloromethane was distilled over calcium chloride and then passed through bas ic a lumina .
Pure acetonitrile was obtained by distillation over calcium hyd r i de .

Purification of the protected nucleotides was achieved by preparative column chromatography on silica gel 60 (0.063-0.2 mesh, Merck) and by preparative thick layer chromatography on silica gel 60 P~2s4 (Merck). Thin layer chromatography ("TLC") was carried out on precoated thin layer sheets F 1500 LS 254 and cellulose thin layer sheets F 1440 from Schleicher ~ Scheull.
The starting material, 6-N-Benzoyl-3-0-tert-butyldimethylsilyl-5'-0-(4-monomethoxytrityl~adenosine (Compound lE) and the reagent 6-N-benzoyl-2',3'-bis-O-(tert-butyldimethylsilyl)-adenosine (Compound lG), are prepared according to Example 1.

a. N6,N6,2',3',5'-O-Pentabenzoyladenosine: (lA) To a suspension of 5.34 g (20 mmole) adenosine (Sigma, dried at 80~C/10-3 Torr for 24 h) in 100 ml dry pyridine, 33.74 g (240 mmole) benzoyl chloride was added dropwise. After 20 h stirring at room temperature (nr.t.") the mixture was treated with 16 ml dry MeOH and then extracted with CHC13 (3 x 250 ml). The organic phase was washed with water (3 x 250 ml), dried over Na2SO4, and evaporated to dryness.
Final coevaporation was performed with toluene. The residue was dissolved in CHC13/MeOH 2/1 by heating, and after cooling to r.t., petrolether (diethylether) was added until the sol~tion became turbid. After standing for 12 h at 0~C 12.18 g was obtained, and from the mother liquor, 2.66 g of the product were isolated as colorless needles of m.p. 183-184~C., yield 14.84 9 (94%).
b. 6-N-Benzoyl adenosine (lB): A solution of 7.88 g (10 mmole) of the pentabenzoyl adenosine (lA) in 150 ml dry pyridine and 50 ml dry MeOH was treated with 50 ml 1 M
sodium methylate solution. After 15 min the solution was poured onto an ice cold solution of a 110 ml DOWEX ion exchanger 50 x 4 (pyridinium form) in ca 20 ml water.
* Trademarks .. .
, .

-19- ~ 3 ~ 3 After 5 h stirring the pH was 5.5-6Ø After filtering from the ion exchanger, the residue was washed with boiling - MeOH/water (3/1). The filtrate was evaporated to dryness and crystallized,from IMeOH/water 2/1 to give 3.25 g (83%) of the product as colorless needles, m.p. 151-153~C.
c. 6-N-Benzoyl-5'-O-(4-methoxytrityl) adenosine (lC): 17.9 9 (46 mmole) 6-N-benzoyl adenosine H2O (lB) was evaporated with dry pyridine (3 x 100 ml) and finally dissolved in 150 ml dry pyridine and 21.31 9 (69 mmole) p-monomethoxytrityl chloride. The reaction solution was stirred at 50~C for 14 h and dry MeOH (50 ml) was added and allowed to come to r.t. The product was extracted with CHC13 (3 x 400 ml) and washed with water (3 x 400 ml). The organic phase was dried over Na2SO4 and evaporated to dryness. Final coevaporation was performed with toluene.
Purification was performed using a silica gel column (16 x 2.5 cm, Merck) and eluted with 3 liter EtOAc/MeOH 7/3 to give 25.6 9 (87%) of an amorphous powder. Crystallization was accomplished with acetone/water to yield the product, m.p. 120-125~C.
d. 6-N-Benzoyl,-2'-O-(tert-butyldimethylsi,lyl)-5'-O-(4-methoxytrityl) adenosine (lD);
6-N-Benzoyl-3'-O-(tert-butyldimethylsilyl)-5'-0-(4-methoxytrityl) adenosine (lE);
6-N-benzoyl-2',3'-O-bis(tert-butyldimethylsilyl)-5'-O-(4-methoxytrityl) adenosine (lF):
To a solution of 4.05 9 (26.9 mmole) tert-butyldimethylsilylchloride ("TBDMS-Cl") and 3.66 9 (53.8 mmole) imidazole in 100 ml dry pyridine, were added 14.42 g (22.4 mmole) of compound lC which was previously coevaporated with dry pyridine. After 15 h stirring at r.t., 5 ml dry MeOH was added and the mixture was evaporated to 1/3 volume. The crude product was extracted with CHC13 (3 x 250 ml) and washed with water. Upon 1 3 ~

evaporation, the crude product was first purified by a silicagel column (15 x 3 cm) with CH2C12/EtOAc (9/1), and - subsequently purified using medium pressure chromatography (silicagel colum~, GSF-type C (N= 9000, VD = 28 ml) at 8-10 bar pressure with the following mixtures of CH2C12/petrolether/EtOAc/EtOH: 100:100:10:0.5 (2 liters), first; 100/100/10/1 (3 liters), second; and 100/100/31/2 (0.5 liters), third. The title compounds were isolated.
The retention time of the peak maxima for each compound was as follows: 25 min. for compound lF (yield 1.84 g, 9%); 60 min. for compound lD (yield 6.62 9, 39g); 105 min. for compound lE (yield 8.32 g, 49~).
e. 6-N-Benzoyl-2',3'-bis-O-(tert-butyldimethyl-silyl) adenosine (lG): 1.74 g (2 mmole) of compound lD was lS stirred with 20 ml 80% acetic acid,at 22~C. After 20 h the cleavage of the monomethoxytrityl group was complete. The reaction mixture was extracted with CHC13 (3 x'200 ml) and washed with 200 ml 1 M phosphate buffer (pH 7). The organic phase was dried over Na2SO4 and evaporated to dryness. Purification was accomplished using a silica gel column (2 x 10 cm) and eluted with CH2C12/MeOH (96/4). The light yellow product was dissolved in 5 ml CHC13 and treated with Et2O until turbid. 0.982 g of the pure product crystallized out. The pure product crystallized out again from the mother liquor, 0.11 9, m.p. 189~C. The total yield was 1.092 g (91%).

-21- ~ 3 3 ~

EXAMPLE lA
Chloro-octahydroazonino-p-nitrophenylethoxyphosphate a. P-nitrophenylphosphoric acid dichloride. To phosphorus trichloride (Fluka, N.Y., ~79690) (28 ml, 0.317 moles) 80 ml anhydrous ether are added. The mixture is cooled to -30~C. P-nitrophenylethanol (8.35 g, 50 mmoles) is added, followed by stirring for 1.5 hr. Ether and excess PC13 is- removed under vacuum to yield p-nitrophenylphosphoric acid dichloride (yield 80%).
b. OctahydrQazonin. Caprylolactam (Fluka, N.Y., ~21631) (25 g, 117 mmoles) is combined with lithium aluminum hydride (10.5 g ) in ether and reduced with stirring for S hr. The reaction mixture is filtered and evaporated with ether. The product is octahydroazonin (9096 yield).
c. l-Trimethylsilyl octahydroazonin. The silylamine of octahydroazonin is prepared by combining octahydroazonin (12.7 g, 0.1 moles) and trimethylsilane (0.12 moles) and O.S moles hexamethyldisilazane + lS0 mg of ammonium sulfate. The mixture is refluxed for 90 hr and distilled under vacuum to yield 16.5 g of l-trimethylsilyl octahydroazonin (82%).
d. Chloro-octahydroazonino-p-nitrophenylethoxy-phosphate. P-nitrophenylphosphoric acid dichloride (26.8 g, 100 mmoles) and l-trimethylsilyl octahydroazonin (19.9 g, 100 mmoles) are combined under nitrogen at 0~C. The mixture is warmed to room temperature and stirred 2-3 h.
Trimethylsilyl dichloride is removed under vacuum. The product in the residue is chloro-octahydroazonino-p-nitrophenylethoxyphosphate (33.9 g, 9496 yield).

1 ~ 3 '3 9 i-~ 3 ~XAMPLE 2 6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-(4-ethoxytrityl)-adenosine-2'-0-(p-nitrophenylethyl)-octahydroazonino-phosphoramidite (2). Compound lE (0.758 g, 1.0 mmole) and diisopropylethylamine (0.52 g, 4 mmole) were dissolved in dichloromethane (5 ml) and chlorooctahydroazonino-p-nitrophenylethoxyphosphane (0.80 9, 2.22 mmole) was added dropwise. After stirring for 2 h at r.t., TLC analysis indicated complete reaction. The reaction mixture was transferred to a separatory funnel using saturated aqueous NaHCO3 (50ml) and the product was isolated by extraction with ethylacetate (2 x 50 ml). The organic ~ayer was washed with saturated NaCl, dried (Na2SO4), and evaporated to dryness. The residue was dissolved in ethylacetate-triethylamine (95:5 v/v~, chromatographed on a silica gel column (10 x 2 cm) previously calibrated with ethylacetate-triethylamine (9/1) and eluted with ethyl-acetate-triethylamine (95:5 v/v).
The product fractions were collected, evaporated to dryness, ~inally coevaporated with dichloromethane and dried in vacuo at 40~C to give compound 2 (1.05 g, 97~) [Anal. calcd. for CsgH70N7OgPSi ~ 1 H2O: C, 64.52; H, 6.60;
N, 8.92. Found: C, 63.93; H, 6.85; N, 8.62].
EXA~PLE 3 6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-monoethoxytrityl-P-thioadenylyl-2'-[OP-(p-nitro-phenylethyl)-5']-6-N-benzoyl-2',3'-di-0-tert-butyldimethylsilyladenosine (4A + 4B). The phosphoramidite 2 (1.12 g, 1.0 mmole) and 6-N-benzoyl-2',3'-di-tert-butyldimethylsilyladenosine (3) (0.478 g, 0.7 mmole) were dried overnight in a drying pistol at 40~C in vacuo. The dried residue was then d;ssolved in dry acetonitrile (6 ml), and 3-nitro-1,2,4-triazole (0.285 g, 2.5 mmole) was added and stirred at r.t. for 3 h. Pyridine (6 ml) and ~3 ~3-~

sulfur (0.5 g) were added and after stirring at r.t. for 20 h, the reaction mixture was extracted with chloroform (300 ml). The organic phase was washed with saturated NaCl-solution (2 x 2Q0 ml), dried (Na2SO4), and evaporated to dryness. Final evaporation was performed with toluene to remove pyridine. The residue was dissolved in chloroform and chromatographed on a silica gel column (15 x 2.5 cm) with 1 liter of chloroform to give a product fraction containing both Rp and Sp isomers. The separation of the diastereoisomers was carried out on preparative silica gel plates, using dichloromethane/ethylacetate/n-hexane (1:1:1 v/v). The plates were developed thrice. The higher Rf isomer (0.47 g; 42%, TLC in dichloromethane/ethylacetate/n-hexane, 1:1:1, 0.54) and the lower Rf isomer (0.31 g; 28%, TLC in dichloromethane/ethylacetate/n-hexane, 0.46) were obtained as colorless amorphous powders after drying at 40~C in vacuo. The higher Rf isomer was compound 4A.
[Anal. calcd. for CgoHggN10O14PSi3 ~ 1 H2O: C, 59.89; H, 6.32; N, 9.61. Found: C, 59.89; H, 6.32; N, 9.21]. 31p_ NMR (400 MHz, CDC13, 85~6 H3PO4, 69.841 ppm). The lower Rf i some r wa s c ompound 4 B . [Ana 1 . ca lcd . for C80H98N10~14PSi3~ ~ 1 H2O: C, 59~.89; H, 6.28; N, 9.61.
Found: C, 59.91; H, 4.61; N, 9.28]. 31p_NMR (400 MHz, CDC13, 85% H3PO4, 69.223ppm). EXAHPLE -4 6-N-Benzoyl-3 ' -0-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5']-6-N-benzoyl-2',3'-di-0-tert-butyldimethylsilyladenosine (5A + 5B).
0.258 g, (0.164 mmole) c>f the pure isomers 4A and 4B, were detritylated separately by treatment of each with 296 p-toluenesulfonic acid in dichloromethane/methanol (4/1) (3.2 ml) at r.t. for 40 min. The reaction mixture was diluted with chloroform (50 ml), washed with phosphate buffer, pH 7 (2 x 20 ml), and evaporated to a foam. The residue was purified by silica gel column chromatography (10 x 2.5 cm).

~ 3 3 ~

Compounds 5A and 5B were separated on the column by using chloroform and chloroform/methanol (100:0.5 till 100:1).
The product fractions were collected and, after evaporation, dried in vacuo at 40~C to give in the case of 5A, 0.198 g (92%), and in the case of 5B, 0.192 9 (89%).
5A has an Rf of 0.27 in dichloromethane/ethylacetate/n-hexane (1:1:1). [Anal. calcd. for C60H82N11~13PSi3S ~ 1 H2O: C, 54.15; H, 6.36; N, 11.57. Found: C, 53.78; H, 6.44; N, 11.72]. 5B has an Rf of 0.30 in the same system.
[Anal. calcd. for C60Hg2NllO13PSi3S: C, 54.90; H, 6.29; N, 11.73. Found: C, 54.90; H, 6.20; N, 11.45J.

P-Thioadenylyl-(2'-5')-adenosine (6A + 6B). The fully protected dimers 5A and 5B, respectively, were deprotected separately by the following procedure. Each protected dimer ~39 m~, 0.03 mmole) was treated with 0.5 M
1,8-diazabicyclor5.4.0]undec-7-ene(1,5,5)(Fluka, cat. no.
33842, "DBU") in pyridine (9 ml), and after stirring at r.t. for 2 h was neutralized with 1 M acetic acid (4.5 ml) and finally evaporated. The residue was taken up in 1 M
tetrabutylammonium fluoride ("Bu4NF") in tetrahydrofuran ("THF~) and after 24 h again evaporated to dryness.
Deacetylation was achieved by treatment with conc. ammonia - (20 ml) for 48 h followed by evaporation of the mixture.
The residue was then dissolved in water (50 ml) and washed with chloroform (2 x 20 ml). The water phase was applied to a DEAE Sephadex*A-25 column (60 x 1 cm) for elution with a linear gradient of a buffer of 0.001-0.25 M Et3NH+HCO3-, pH 7.5. The product was eluted at a concentration of 0.08-0.1 M. Evaporation to dryness followed by coevaporation with water (10 x 10 ml) and final purification by paper chromatography with i-PrOH/conc. ammonia/water (7:1:2 v/v) yielded in the case of 6A 630 O.D. units (87.5%) and in the * Trademark "

-25- 1~ 3gi3~3 case of _ 648 O.D. units (90~). The Rf of 6A on cellulose sheets, using the above system, was 0.29. The Rf of 6B was 0.30.

6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-monomethoxytrityl-P-thioadenylyl-2'-~0P-(p-nitro--phenylethyl)-5'~-N-6-benzoyl-3'-0-tert-butyldimethylsilyl-P-thioadenylyl-2l-tQp-~p-nitrophenylethyl)-5~]-6-N-benzoyl-2',3'-bis-0-tert-butyldimethylsilyladenosine (7A, 7B and 8A, 8B). The phosphitamide 2 (0.449 g; 0.41 mmole~ was condensed with the 5'-hydroxy dimer SA and 5B (0.0262 g;
0.2 mmole) separately in the presence of 3-nitro-1,2,4-triazole (0.114 g; 1.0 mmole) in dry acetonitrile (3.2 ml).
After stirring at r.t. for 3 h, sulfur (0.2 g; 6.25 mmole) in pyridine (0.4 ml) was added for oxidation. After stirring at r.t. for another 24 h, the product was extracted with dichloromethane (50 ml), the organic phase was washed with saturated NaCl solution (2 x 20 ml), dried (Na2SO4), and then evaporated to ~dryness. ~inal coevaporation was performed with toluene to remove pyridine. The crude product was chromatographed on a silica gel column (lS x 2 cm) and eluted with chloroform/methanol (100:2) to give,~on condensing with compound 5A, the isomer mixture 7A + 7B. The isomer mixture 8A + 8B, was obtained upon condensing the phosphitamide 2 with compound 5B in the same manner. The diastereomeric separation of each isomer mixture was accomplished by using preparative silica gel plates (20x20x0.2 cm) to which about S0 mg of isomer mixture per plate was applied for optimal separation. The plates were developed in dichloromethane/ethylacetate/n-hexane (l:l:O.S
v/v) three times. The appropriate bands were cut out and eluted with chloroform~ethanol (4:1) The higher Rf isomer synthesized from 5A has a Rf of 0 58 in 1~ 3~ ~3 dichloromethane/ethylac~ tate/n-hexane (1:1:1) and yielded 4 8 % ( 0 . 2 1 8 9 ) o f- 7 A . ~ A n a 1 . c a 1 c d . f o r C111~135N17~22P2Si4S2 ~ 1 H2O: C, 57.S6; H, 5.96; N, 10.28.
- Found: C, 57.38; H, 5.99; N, 10.11] . The lower Rf isomer has a Rf of 0.48 in the above-mentioned system, and yielded 3 4 % ( 0 . 1 5 7 g ) o f 7 B . 1 An a 1 . c a 1 c d . f or ClllH135N17~22P2Si4S2 ~ 1 H2O: C, 57.56; H, 5.96; N, 10.28.
Found: C, 57.40; H, 5.97; N, 10.193.
The isomeric mixture derived from the 5 ' -hydroxy dimer 5B
was separated in the same manner and yielded the higher Rf isomer 8A in 41% (0.186 g ) with an Rf of 0.53 in the above solvent system. lAnal. calcd. for ClllH135N17~22P2Si4S2 C, 58.02; H, 5.92; N, 10.36. Found: C, 58.00; H, 5.84; N, 10.66] . The lower Rf isomer 8B showed a Rf value of 0.45 a n d y i e 1 d e d 3 5 % ( 0 . 1 6 1 9 ) . [ A n a 1. c a 1 c d . f o r ClllE~135N17022P2Si4S2 1 H2O C, 57.56; H, 5.96; N, 10.28. Found: C, 57.30; H, 5.78; N, 10.03~.
EXA~PLE 7 ( Rp ) -P-Th ioadenylyl- (2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- (2 ' -5' ~-adenosine (9A). A solution of 0.116 g (0.05 rrunole of the fully protected trimer 7A was detritylated with 2% p-toluenesulfonic acid in 1.5 ml dichloromethane/methanol (4: 1) for 90 min. The mixture was dissolved in CHC13, washed with phosphate buffer (2x15 ml), dried (Na2SO4), and evaporated to dryness. The residue was chromatographed on silica gel plates ( 20x20xO . 2 cm), developed with dichloromethane/ethylacetate/n-hexane ~5:5:3 v/v). The product band (Rf 0. 35) was cut out, eluted with chloroform/methanol (7: 5) and gave on evaporation to a colorless foam a yield of 70-83~. 38.5 mg (18.9 micromole) of the product was then stirred with 0.5 M DBU in pyridine (7.5 ml) for 20 h, neutralized with lM acetic acid (3.75 ml) and finally evaporated. The evaporated product was desilylated through treatment with lM B~14NF in THF (6 ml) ~ 3 ~ 9 '.~

for 24 h. The mixtur-e was concentrated in vac~o. The residue was dissolved in conc. ammonia (25 ml) and stirred at r.t. for 48 h. After evaporating the solution, the residue was taken up in water (20 ml) and washed with chloroform (2xlO ml). The aqueous phase was put on a DEAE
Sephadex A-25 column (60xl cm) and the product was eluted with a linear gradient of Et3NH+HC03-buffer. The product fraction was collected, evaporated and further purified by paper chromatography using i-PrOH/conc. ammonia/water (6:1:3) to give the title compound in 75-80~ yield.

(Sp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine ~9B). A solution of 0.116 9 (0.05 mmole~ of the fully protected trimer 7B was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.

(Rp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5')-adenosine (lOA). A solution of 0.116 g (0.05 mmole) of the fully protected lrimer 8A was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.

(Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine ~lOB). A solution of 0.116 9 (0.05 mmole) of the fully protected trimer 8B was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
The UV-absorption spectra in methyl alcohol and lH-~MR spectra of the above-prepared protected monomer, dimer and trimer cores are set ~orth in Tables 1 and 2, respectively.

-28- ~3~ ,3 W-Absorption Spectra of Protected Monomer, Dimer and Trimer Cores in MeOn Compound ~max (nm) 19~

_ 230 277 4.47 4.50 4A 231 277 4.66 4.70 4B 231 277 4.66 4.70 5A 278 4.70 5~ 278 4.70 7A 230 278 4.78 4.90 7B 230 278 4.78 4.89 8A 230 278 4.79 4.90 8B 230 278 4.78 4.90 lH-NMR Spectra of Protected Monomer, Dimer and Trimer Cores Con~
pound 1 '-H 2-~ 8-H Solvent 2 6.11 6.13 8.70 8.23 CDC13 4A 6.30d 5.87d 8.68; 8.60 8.19; 8.17 CDC13 4B 6.29d 5.94d 8.72; 8.62 8.26; 8.18 Cl)C13 5A 6.06d 5.94d 8.82; 8.75 8.25; 8.08 CDC13 5B 6.13d 5.90d 8.74; 8.73 8.26; 8.24 CDC13 7A 6.23d 6.08d 5.84d 8.69; 8.58; 8.55; 8.20; 8.11;8.01 CDC13 7B 6.22d 6.17d 5.85d 8.67; 8.60; 8.57; 8.23; 8.10;8.00 CDC13 8A 6.27d 6.13d 5.93d 8.71; 8.61; 8.60; 8.21; 8.13;8.00 CDC13 8B 6.27d 6.22d 5.90d 8.71; 8.64; 8.61; 8.27; 8.22;8.19 CDC13 1 ~values in ppm; Standard T~lS; characteristic 3 0 s i 9 na 1 s 1 3 3 ~ 3 Assiqnment of Absolute Configuration of 2',5'-Phosphorothioate Adenylate Trimer Cores Determination of the absolute configurations of the trimer cores was accomplished by 31P-NMR fast bombardment mass spectrometry and enzymatic digestion.
It is known that the enzyme SVPD preferentially cleaves Rp-3',5'- or 2',5'-phosphorothioate linkages from the 2'/3'-terminus. Nelson et al, J. Org. Chem. 49:2314-2317 (1984); Eppstein et al, J. Biol. Chem. 261:5999-6003 (1986); Lee et al, Biochemistry 24:551-5S5 (1985). SVPD
hydrolysis of the chemically synthesized dimer core ARpA
yielded adenosine and AMPS in a molar ratio of 1:1, respectively; the half-life was 3 hours (Table 3). The ASpA dimer core was not a substrate for SVPD under these conditions. Trimer core 9A has the Rp ~ internucleotide linkage con iguration as determined by hydrolysis by SVPD
to yield AMPS plus ARpA in a molar ratio of 1:1, respectively. Similarly, SVPD hydrolysis of trimer core 9B
yielded ASpA and AMPS, thus identifying trimer core 9B as having the SpRp internucleotide linkage configuration (Table 3). Trimer cores 10A and 10B were not substrates for SVPD (Table 3), revealing the presence of the Sp configuration in the internucleotide linkage adjacent to the 2'/3'-termini.

1339.iJ.~3 ~ " ~, .. ..
o ' oc ~U ~ Q 0 ~~ O ~ 0 0 V~ ~ ~ Q
L
O C
~ O O ~ 0 0 ~ CJ
O ~ J ~,_ ~ > > > >
~' .~ O Q '_ 0 ~ 0 0 . ~'1-- J O O O ~> C
L. ~ _ C~
~_ O O 1~ C Z
O ~ L L
~_ o o '~ . E
O O O O O O
0 ~- c cn~ c c c o ~ O L Q
0 L ._ ~ J
O
O ~~-- ~O
~ ~r ~-- c c<n C
O ~1 ~ ~ 0 ~~ 0 -n I E
_ ~ 0 0 ~ ~ ~ ~
~,~ ~ ., ~ ~ ~ O
L S -- 0 0 0 0 ~ 0 O ~ o O
", ~' X .------ -- C 0 L E
O ~ ~' ~_ _ V U O O O O
O ~~ C CC~~. C ~ I
_ O J
O ~ ~ O
L ~o ~ ., Z ~' ~ _ c _ C ~ 1 0 -- ~ ~ 0~ 0 0 0 ~_ ~ > ~ ~ r~

C ~ O O ~ O
C~ _ J J Cl O
C Z _ ~
._ ~L C
oV~ O ~ ~ E ~ 0 ~- L ~ 0 .
~1 _ ~ Z
~ O
._ 0 r C

O ~u~
,.~ .. .... 00 O' ~ O~ V~O' -- --~ O O
J l. . . .>~ :~
~: ~ ~ 0 u 0 o o ~J ~ ~' ' '~ E e E
~ Oa ~ ~ --~ Z ~ ~O ~ ~ u~
c ~ ~ I~ ~ I~ o ~ C C C
o o o O
O ~ o. ~
0 ~ "
~1 0 0 ~' ~' C
L o ~ ~ C C ~
~_ ~ o ~ o o ~
v- O ~1 ~ E E O
r ~ e~ ¦ol ~ ol ~ ~ ~ C C
'01 '01 0 O~ O~ ~ ~ O O O -- --- ~~
O E <~
U~ E . 0 ~ ~ ~~ a 0 I
N ~ ~ ~t ~ ~ ~ < > ~

~3~3-~3 The four 2,5-phosphorothioate adenylate trimer cores were further characterized by hydrolysis with the enzyme 2'-phosphodiesterase ("2'-PDE"), an exoribonuclease found in L cell extract. The enzyme cleaves from the 2'/3'-terminus. Whereas authentic A2 and A3 cores where hydrolyzed to adenosine and AMP with a half-life of 10 min, the dimer cores ARpA and ASpA were not substrates for 2'-PDE (Table 3). The fact that the 2,5-phosphorothioate dimer cores were not substrates for 2'-PDE (unlike authentic 2-5A) greatly assisted in the assignment of the stereoconfigurations of the 2',5'-phosphorothioate adenylate trimer cores. Trimer core 9A was a substrate for 2'-PDE; the products of hydrolysis were ARpA and AMPS.
Trimer core 9B was a substrate for SVPD, yielding ASpA and AMPS; trimer core lOA was a substrate, yielding ARpA and AMPS; trimer lOB was not a substrate for 2'-PDE.
31P-NMR spectroscopy has revealed that _p stereoisomers of phosphorothioates resonate to higher field than Rp diastereomers. Further, Sp diastereomers have a longer retention time on reverse phase HPLC than Rp diastereomers . The ASpA dimer core resonates upfield from the ARpA (Table 3). Similarly, two singlets observed for ASpAspA resonate upfield from the two singlets observed for ARpARpA (Table 3). Assignment of the absolute configurations of trimer cores 9A (RpRp) and lOB (Sp_p) was based on the two singlets which resonate at the same frequency as the singlets observed for the ARpA and ASpA
dimer cores. Assignment o~ configurations for trimer cores 9B and lOA was made in combination with the enzyme degradations and HPLC analyses (Table 3). The 3IP-NMR
spectra revealed that the ~ppm between the two singlets for the ASpARpA trimer core is 1.2, whereas the two singlets for the ARpAspA have a ~ppm of 0.8 (assignment is 5' to 2'/3' terminus).

-33- ~3~3i.l ,3 The metabolic stability of the 2,5'-phosphorothioate dimer and trimer cores is markedly greater than authentic 2-5A. The rate of hydrolysis of the trimer cores by the 3'-exonuclease SVPD is, in order of decreasing stability:
AspAp~pA>ARpARpA>>>A3~ The trimer cores ARpASpA and ASpAspA
are not substrates of SVPD (Table 3). The 3'->'5'direction of stepwise cleavage by SVPD is blocked by an _p configuration, preventing cleavage of the upstream adjacent phosphorothioate linkage. With 2'-PDE, the ARpARpA, ASpARpA and ARpASpA trimer cores, but not the ASpAspA
trimer core, were substrates. With both SVPD and 2'-PDE, the dimer cores (either ARpA or ASpA) accumulate following hydrolysis of the ARpARpA, ASpARpA and ARpASpA trimer cores. Hydrolysis of the 2-5A molecule by SVPD and 2'-PDE
proceeds from the 2'/3'-terminus. Therefore, introduction of the phosphorothioate group into tne trimer core results ;n the accumulation of the ARpA or ASpA dimer cores from the 5'-terminus and the accumulation of AMPS from the 2'/3'-terminus (Table 3). With authentic A3, there is no detectable accumulation of A2 following hydrolysis by SVPD
or 2'-PDE.
None of the _p linkage-containing tri~er cores were cleaved by SVPD. While the half-life of ASpARpA upon cleavage by L-cell extract (15 hours) did not differ significantly from that of ARpARpA (18 hours), the half-life for the ARpASpA trimer was orders of magnitude longer (20 days). ASpAspA was not cleaved ~y L-cell extract (Table 3).
Preparation of Phosphorothioate Tetramer Cores The following non-limitin~ examples illustrate the preparation of the fully-resolved tetra~f core co~pounds of the invention.

-34- 13 3~ g-)3 a. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5)-adenosine b. (Rp)-P-thiodenylyl-(2~'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5')-adenosine.
A solution of 0.149 g (0.065 mmole) of fully protected trimer 8B, which has the stereoconfiguration SpSp, was detritylated with 2% p-toluenesulfonic acid in 1.5 ml dichloromethane/methanol (4:1) for 3 h at room temperature. The mixture was diluted with 50 ml CHC13, washed with phosphate buffer (2 x 15 ml), dried (Na2SO4), and evaporated to dryness. The residue was chromatographed on silica gel plates (20 x 20 x 0.2 cm) developed with dichloromethane/ethylacetate/n-hexane (5:5:3 v/v). The product band, Rf 0.55, was cut out, eluted with chloroform/ethanol (1:1) and gave, on evaporation to a colorless foam of 0.108 9 (yield 88~). The 5'-deblocked _pSp trimer 8B (101 mg; 0.05 mM) was dissolved in 0.5 ml acetonitrile overnight with phosphitamide 2 (0.105 g; 0.1 mmole). 3-Nitro-1,2,4-triazole (0.023 g; 0.2 mmole) was added. After stirring at room temperature for 3 h, sulfur (0.042 9; 1.3 mmole) in pyridine (0.084 ml) w~s added for oxidation. After stirring at room temperature for another 24 h, the product was extracted with dichloromethane (50 ml), the organic phase was washed with saturated NaCl solution (2 x 20 ml), dried over Na2SO4, and then evaporated to dryness. Final coevaporation was performed with toluene to remove pyridine. The crude product was purified by using pre~arative silica gel plates (20 x 20 x 0.2 cm) to which about 50 mg per plate was applied for optimal separation by developing in dichloromethane/
ethylacetate/n-hexane (1:1:0.5 v/v) three times. The band containing the~fully protected SpSp_p tetramer (Rf 0.3) and the band containing the fully protected P~pSp_p tetramer (RF

133~3 )3 0.4), were cut out and eluted with chloroform/methanol (4:1). The yield of the fully protected Sp~pSp tetramer was 43 mg; 29%. The yield of the fully protected ~pSpSp compound was 53 mgi 35.5%. The two isomers (7.3 micromoles; 0.22 mg) were deblocked by stirring with 0.5 M
DBU in pyridine (5.0 ml) for 20 h, neutralized with lM
acetic acid/ pyridine (0.5 ml) and finally evaporated. The subsequent desilylation was achieved with lM
tetrabutylammonium fluoride in tetrahydrofuran (3.6 ml) for 48 h at r.t. The mixture was concentrated in vacuo, the residue dissolved in conc. ammonia (15 ml) and stirred at r.t. for 48 h. After evaporating the solution, the residue was taken up in 5 ml of 80~ acetic acid and allowed to stand for 20 h at r.t. The residue was dissolved in about 5 ml water and put on a DEAE Sephadex A-25 column (60 x 1 cm) and the product was eluted with a linear gradient of Et3NH+HCO3- buffer (pH 7.5) (gradient 0.001 - 1 M). The product fractions were collected, evaporated and further purified by paper chromatography using; i-PrOH/conc.
ammonia/water (6:1:3). The tetramer isomers were eluted with water to give ASpAspAspA (72% yield; Rf 0.23) and ARpASpAspA (73% yield; Rf 0.29) as the ammonium salt.

a. (Rp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine b. (Sp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine 13 ~ ~.3 ~

The title compounds are prepared by following the procedure of Example 11, but substituting the fully - protected trimer 7A for 8B as the starting material.

a. (Rp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5i)-adenosine b. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine The title compounds are prepared by following the procedure of Example 11, but substituting the fully protected trimer 7B for 8B as the starting material.

a. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5'j-(Sp)-P-thioadenylyl-(2'-5')-adenosin,e - b. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2~-5~ ? - ( sp ) -P-thioadenylyl-(2'-5')-adenosine The title compounds are prepared by following the procedure of Example 11, but substituting the fully protected trimer 8A for 8B as the starting material.
20 - Preparation of 2'~5'-Phosphorothioate Oligoadenylalte 5'-Monophosphates 5'-Monophosphates of 2',5'-oligoadenylates are readily prepared by reacting the corresponding core compounds with POC13. Such treatment would result in the elimination of sulfur from the phosphorothioate internucleotide linkages of the compounds of the present invention, and the formation of 2-5A. Thus, the 5'-monophosphates of the phosphorothioate oligoadentylates must be prepared from the corresponding fully protected core compounds from which the monomethoxytrityl blocking group on the 5'-terminal nucleotide has been removed. The conditions of the phosphorylation must be such that the p-nitrophenylethyl blocking groups on the internucleotide phosphorous atoms remain intact.

~33~53 The 5'-monophosphate of each resolved trimer core of the present invention was prepared from the 5'-hydroxy - analogue of the corresponding fully protected trimer 7A, 7B, 8A or 8B. The intermediate 5'-phosphotriester (11A, 11B, 12A or 12B) was prepared according to Example 15 and then freed of all blocking groups according to Example 16 to yield the 5'-monophosphate. The procedure of Examples 15 and 16 may be used for forming the 5'-monophosphate of any of the four trimer core stereoisomers.

5'-0-(2,5-Dichlorophenyl-p-nitrophenylethyl)-phosphoryl-6-N-benzoyl-3'-O-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5']-6-N-benzoyl-3'-O-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5'~-6-N-benzoyl-2',3'-di-O-tert-butyldimethylsilyl adenosine (llA, 11B, 12A or 12B): To a solution of 1,2,4-triazole (0.011 g; 0.16 mmole) and 2,5-dichlorophenylphosphorodichloridate (O.022 g; 0.018 mmole) in dry pyridine (0.5 ml) was added the 5'-deblocked analogue of either 7A, 7B, _ or 8B (0.1 9; 0.049 mmole) (~repared as an intermediate in Example 11), and after stirring for 30 min, p-nitrophenylethanol (0.02g; 0.119 - mmole) was added and stirring continued for 20 h. The solution was then extracted with chloroform (50 ml), the organic phase was washed with water ( 2 X 20 ml), evaporated to dryness, and finally co-evaporated with toluene. The residue was purified by silica gel chromatography on preparative plates ( 20 X 20 X 0.2 cm) using the system dichloromethane/n-hexane/ethylacetate (1:1:1 v/v). The product band was eluted with chloroform/methanol (4:1) and evaporated -in vacuo to give 11A, 11B, 12A or 12B in 70-80%
yield, respectively.

t 3~9a3 a. 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine (13A) b. 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine (13B) c. 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine (14A) d. 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine (14B) p-Nitrobenzaldoxime (0.036 g; 0.216 mmole) was stirred for 30 min in dioxane/triethylamine/water (each 0.5 ml), the appropriate 5'-phosphotriester llA, llB, 12A or 12B (0.05 g, 0.02 mmole) was added and the mixture was kept at r.t. for 4 h. The solution was evaporated to dryness, followed by coevaporation with toluene ~2x5 ml), and the residue purified by preparative TLC on plates (20x20x0.2 cm) in chloroform/methanol (95:5). The product band was eluted with chloroform/methanol/triethylamine (5:1:1) and evaporated to dryness. This material (0.022 g;
10 micromole) was stirred with 0.5 M DBU in pyridine (8 ml) at r.t. for 24 h, the solution neutralized with lM acetic acid (4 ml) and evaporated to dryness. The residue was - treated with lM Bu4NF in THF (6 ml) for 48 h and after evaporation the debenzoylation was accomplished by treatment with conc. ammonia (25 ml) at r.t. for 48 h. The solution was evaporated. The deblocked crude trimer 5'-monophosphate was taken up in water (25 ml) and washed with chloroform (2x10 ml). The aqueous phase put on a DEAE
Sephadex A-25 column (60xl cm) for elution with a linear gradient of 0.001-lM Et3NH+HCO3- buffer. The product fractions were collectecl, evaporated to dryness, and after several coevaporations with water were further purified by paper chromatography using the i-PrOH/conc ammonia/water-system (55:10:35) The product band was eluted with water 13:~'33~

and gave on lyophilization the trimeric P-thioadenylate 5'-monophosphate 13A, 13B, 14A or 14B as ammonium salts in 68-74~ yield.

-39a-1~'.39.3.'j3 Z ~Z
z~z o~~ 1l o (~) I
7~ o~
~ ~ ~3 Z t~) ¦

0--~--0 ~
.. " {~) I
O ~Z

I~

a:l z ' ~ 7~

o O

O C~. Z
O--~L=O ~ O
O ~

~
Z

-40- ~39~

The lH-NMR of the 5'-monophosphates are as follows:

l~-NMR Spectra of 5'0-Phosphory~
P-thioadenylyl-(2'-5'~-P-thioadenylyl 5 -(2'-5')-adenosine Stereoisomer~

Com~ H 2-H 8-H Solvent pound 13A 6.04 5.92d 5.75d 8.31;8.18; 8.12; 7.98; 7.85; 7.80 D2O
13B 6.12s 5.94d 5.76d 8.26; 8.21; 8.11; 7.99; 7.94; 7.86 D2O
14A 6.03s 5.92d 5.80d 8.27; 8.22; 8.15; 8.04; 7.93; 7.81 D20 14B 6.09s 5.94s 5.81d 8.41; 8.26; 8.14; 8.07; 8.02; 7.89 D2O

2 ~values in ppm; Standard TMS; characteristic signals 13391~-~3 Monophosphorylation of the 5'-deblocked protected trimers to form the 5'-phosphotriesters llA, 11B, 12A or 12B proceeds in high yield, 70-80~, followed by the further high yield (68-74%) step of complete deprotection resulting in the trimer 5'-monophosphates 13A, 13B, 14A or 14B.
~ The 5-monophosphates of each resolved tetramer core compound of the present invention is prepared in the same fashion, using the identical molar quantities as in Examples 15 and 16 except that the starting material for the synthesis is the 5'-hydroxy analogue of the fully protected tetramer rather than the 5'-hydroxy analogue of the fully protected trimer. The following fully resolved tetramer 5'-monophosphates are thus prepared:
5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-- thioadenylyl-(2'-5' ? - ( sp ) -thioade,nylyl-(2'-5')-aden,osine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioaden~ylyl-(2'-5'~)-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphory,l-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl--(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioad,enylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine -42- ~3~3.~3 Preparation of 2',5'-Phosphorothioate Oliqoadenylate 5'-Diphosphates and 5'-Triphosphates The 5'-diphosphate and 5-triphosphate of the 2',5'-phosphorothioate oLigoadenylates may be prepared from the 5'-monophosphate by following the procedure of Example 17.

All reactions are performed in glassware oven-dried at 125~C for 18-24 hr. A 2',5'-phosphorothioate oligoadenylate ster-eoisomer (trimer or tetramer, 400 OD
units at 260 nm) is dissolved in 500 microliters of dry dimethylformamide ("DMF") and dried in vacuo in a 10 ml conical flask at 35~C. This process is repeated three times. To the dry residue, 50 micromoles of triphenylphosphine, 100 micromoles of imidazole and 50 micromoles of dipyridinyl disulfide are added. The mixture is dissolved in 500 microliters dry DMF plus 50 microliters of dry dimethylsulfoxide. The solution is stirred with a stirring bar for 2 hr at room tempe~ature. After 2 hr the solution is homogeneous (after 30 minutes, the solution begins to change to yellow). The solution is transferred dropwise to 10 ml of a 1% NaI/dry acetone (w/v) solution.
The clear white precipitate which forms is the sodium salt of the 5'-phosphoroimidazolidate. The precipitate is centrifuged at room temperature, the supernatant is decanted, and the precipitate is washed three times with 10 ml dry acetone. The centrifuging is repeated. The precitipate is dried over P2Os in vacuo for 2 hr. The precipitate is dissolved in 200 microliters of freshly prepared 0.5 M tributylammonium pyrophosphate in dry DMF.
The solution is maintained at -room temperature for 18 hr after which time the DMF is removed in vacuo. The residue is dissolved in 0.25 M triethylammonium bicarbonate buffer ("TEAB") tpH 7.5). The 5'-di and 5'-triphosphate products are separated using a DEAE-Sephadex A25 column (HCO3 form -43- 13~9~3 1 x 20 cm) with a linear gradient of 0.25 M to 0.75 M TEAB.
Fractions (10 ml) are collected. The product is observed by ultraviolet spectroscopy at 254 nm. The fractions containing the 5'-di- and S'-triphosphates are separately pooled and dried in vacuo. The TEAB is removed by repeated addition of water followed by lyophilization. The yield of the 5'-diphosphate is about 5%; the yield of the 5'-triphosphate is about 6096.

It is genera:lly regarded that activation of RNase L
by 2-5A is key to the antiviral defense mechanisms.
Interferon induces transcription of the enzyme 2-5A
synthetase which produces 2',5' linked oligoadenylates upon activation of double-stranded RNA. The only known biochemical effect of 2-5A is activation of RNase L. This enzyme hydrolyses mRNA and rRNA, thereby resulting in inhibition of protein synthesis. The activation of RNase L
is transient unless 2-5A is continuously synthesized, since 2-5A is rapidly degraded. RNase L activation thus plays a critical role in inhibiting replication, and therefore in defending against infection by viruses.
According t~ the invention,- all four of the 2',5'-phosphorothioate adenylat-e trimer cores, and their 5'-monophosphates bind to RNase L, as determined by radio binding assay according to the method of Knight et al, Heth . Enzymol . 79: 216-227 ( 1981 ). The 2 ', 5 ' -phosphorothioate adenylate trimer cores and authentic A3 were able to displace p3A4~32P]pCp probe from RNase L in L929 cell extracts in a concentration-dependent manner (Fig. lA). IC50s varied from 2 x 10-6 to 5 x 10-6 M.
However, the 5'-monophosphorylated trimers had 1000-fold higher binding aff-inity to RNase L than their respective cores, that is, ICsos ranged from 2 x 10-9 to 5 x 10-9 M
(Fig. lA). ~Jithout wishing to be bound by any theory, this ~ 3 3 ~ 3 increase may be attributed to the ability of the 5'-monophosphates to anchor the molecule to RNase L more - effectively because of increased polarity.
The 2',5'-phosphorothioate cores, with one exception, have the correct stereoconfiguration to activate RNase L.
The activation of partially-purified RNase L by the 2',5'-phosphorothioates was measured according to the core-cellulose assay of Silverman, Analyt. Biochem. 144:450-460 (1985) which relies on hydrolysis of the substrate polytU)-3-[32PlpCp. Surprisingly, three of the four 2',5'-phosphorothioate adenylate cores were able to activate RNase L to cleave poly(U)-3'-[32P]pCp in the core-cellulose assay. (Figure lB) The order of activation of the trimer cores and the corresponding 5'-monophosphates is:
~pRp>SpRp>_pSp (Fig. lB). While pARpARpA was the most efficient activator of RNase L, the compound is metabolically unstable and is readily attacked by phosphodiesterases (See Table 3). The Sp_p trimer core did not activate RNase L, even at a concentration of 10-3 M. As was observed in the binding assay (Fig. lA), there was a 1000-foLd increase in the activation of RNase L
by the 5'-monophosphates of the 2',5'-phosphorothioate trimers compared to their respective cores.
Activation of RNase L by 2',5'-phosphorothioate adenylate trimer cores and their 5'-monophosphates was also measured in an rF'NA cleavage assay using L929 cell extracts. ARpAF~pA and ASpARpA activated RNase L to cleave 28S and 18S rRNA to specific cleavage products at 10-5 M.
However, ARpASpA and ASpAspA did not activate RNase L at concentrations as high as 10-4 M. It appears that the rRNA cleavage assay was not sensitive enough to detect activation of RNase L by ARpASpA Under the experimental conditions used, aulhentic A3 core was also inactive, which ~ 3~9;3 is in agreement with previous reports (Haugh et al, Eur. J
Biochem. 132:77-84 (1983)).
The corresponding 5'-monophosphates pARpARpA~
pASpARpA (at 10-8M) and pARpAspA (at 10 7 M) activated RNase L to cleave 28S and 18S rRNA. Authentic pA3 was active at 10-6 M. Incubation with pASpAspA, even at coneentrations as high at 10-5 M, did not result in detectable rRNA degradation.
The increased bonding strength of the 5'-phosphorylated triMer eore ARpASpA provides a relatively metabolically stable and highly efficient activator for RNase L.
ASpAspA and corresponding 5'-monophosphate were observed to inhibit RNase L activation in both the eore-cellulose and rRNA cleavage assays. Notwithstanding, these compounds are extremely useful as probes in the evaluation of the role of RNase L in the interferon-induced biological eascade. Most importantly, pAspAspA seleetively inhibits aetivation of RNase L at physiologieal coneentrations, and is metabolically stable to speeific and non-specific phosphodiesterases. The molecule provides the means to selectively shut off RNase L activa~ion.
Individuals afflicted with chronic myelogenous leukemia ("CML") display a highly elevated RNase L
activity, as evide~ced by novel rRNA CML-speeifie eleavage products. Thus, pAspAspA~ which is a metabolically stable inhibitor of RNase L, has potential utility in treating myelogenous leukemi 3 .
pAspAspA is the most effective inhibitor of RNase L
reported to date. Moreover, notwithstanding its RNase L
inhibitory effect, pAspAspA is observed to inhibit HIV
reverse transcript:ase activity and tobacco mosaic virus replication.

-46- 133~ 33 ~or phaLmaceutical use, the compounds of the invention m~y be taken up in pharmaceutically acceptable carriers, such ~s, solutions, suspensions, tablets, capsules, ointments, elixirs and injectable composition and the like. They are ad~inistered to subjects sufferin~ from viral infection. The dosage administered depends upon the nature and severity of the infection, the disease stage, and, when administered systematically, the size and weight of the infected subject.
- The compounds are generally administered in the form of water-soluble salts. Pharmaceutically acceptable water soluble salts include, for example, the sodium, potassium or ammonium salts of the active compounds. They are readily dissolved in water or saline solution. Thus, the preferred ~ormulation for pharmacological use comprises a saline solution of the desired compound in salt form. The formulation may further contain an agent, such as a sugar or protein, to maintain osmotic balance. The salt form of the compound is preferred owing to the relatively high acidity (about pH 3) of the acid form of the compounds.
The compounds of the invention may be used to treat or protect humans and animals from viral infectives such as Herpes simplex, rhinovirus, Epstein Barr virus, measles virus, multiple sclerosis (which may be caused by a viral agent) and the various Human Immunodeficiency Viruses ("HIV") such as HIV-I, which causes cutaneou~ T cell lymphoma, HIV-2, which causes Sezary lymphoma, and HIV-3, which is responsible ~or ~cquired immune deficiency syndrome ("AIDS"). The compounds of the invention inhibit the reverse transcriptase activity of HIV.
The compounds may be applied topically to treat skin cancers caused by radiation, carcinogens or viral agents.
Such skin cancers include cutaneous T-cell lymphoma, Sezany lymphoma, Xeroderma pigmentosium, ataxia telangiectasia and -~7- ~ ~ ~g33i~)3 Bloom's syndrome. A sufficient amount of a preparation containing a compound of the invention is applied to cover - the lesion or affected area. An effective concentration of active agent is between about 10-3 M and 10-5 M, with 10-4 M being preferred.

6056-5~

Effect of 2',5'-Phosphorothioate Oligoadenylates on HIV Reverse Transcriptase Activity HIV reverse transcriptase (RNA-dependent DNA
nucleotidyl-transferase) activity was assayed by a modi~ication of the procedure of Poiesz et al. (Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., Bunn, P.S., Minna, J.D., and Gallo, R.C., Proc. Natl. Acad. Sci. U.S.A. 77:, 7415-7419 (1980~).
Cultured H-9 cells are grown at 106 cells/ml il RPMI-1640 ~edium and 20% heat-inactivated fetal calf serum.
Cell suspensions are centrifuged (1000 x 9, 10 min.) and the supernatant is removed. Virus particles are precipitated from this cell-free supernatant to which 0.3 ml of 4 M NaCl and 3.6 ml of 30~ tweight/volume) polyethylene ~lycol are added. The suspension is placed on ice for 2 hr following centrifugation at 15,000 x g for 30 min at 0~C. The precipitate is resuspended in 200 microliters of 50% glycerol (vol./vol.)/25 mM Tris-HCl (pH
7.5)/5 mM dithiothreitol/50 mM KCl/0.025~ Triton*X-100.
Virus particles are lysed by the addition of 100 microliters of 0.9% Triton X-100/1.5 M KCl. Reverse transcriptase assays are performed at 37~C for l hr with 10 microliters of the lysed virus solution in a final reaction volume of 100 microliters containing: 40 mM Tris-HCl (pH
7.8), 4 mM dithiothreitol, 45 mM KCl and 2.5 micrograms of template primer [Poly(A)-dT15. 0.5 micro~rams/microliter]
(with a final Mg++ concentration of 10 mM). At this time, 10 microliters of the 2',5'-phosphorothioate oligoadenylate is added to a final concentration of 200 micromolar.
Reaction mixtures also contain 4 micromoles of ~3H]dTTP.
Reactions are stopped by the addition of cold 5%
trichloroacetic acid and filtered through nitrocellulose discs. The discs are dried and the radioactivity bound to * Trademark 1339~ ~3 the discs is determined. Reverse transcriptase activity is expressed as the percent relative to a control.
The data is ,hown in Table 5. The compounds were assayed in the above manner in two sets, each set having a separate set of controls. The compounds of reactions 1-4 were assayed against control ~1, which was 187 x 103 cpm.
The compounds used in reactions 5-13 were assayed against control ~2, which was 273 x 103 cpm.

-50- 13 ~9 ~3 TABL E S
Inh ibi t ion of HIV (HTLV-IIIBH-g) Reverse Transcriptase Activity by 2',5'-Phosphorothioate Oligoadenylates Reaction Compound Concentra- Reverse Trans- Percent No. - tion criptase Inhibi-Activity tion (uM) (cpm x 10-~) 1 p3A3 200 187 0 2 pA3 200 133 29 4 2ARpARpA 200 144 25 pASPARPA 200 230 16 6 PARpASpA 200 206 25 7 pAspAspA 200 232 15 8 RpARpA 200 224 18 9 ASpARpA 200 258 6 ARpASpA 200 247 10 11 ASpAspA 200 219 20 12 AspAspAspA 200 149 45 13 ARpAspAspA 200 147 46 1~ 3~'3~3 Although p3A3, pA3 and A3 are found in mammalian cells, only the monophosphate inhibits HIV reverse transcriptase. The core compounds of the present invention on the other hand are observed to inhibit HIV reverse transcriptase. While all the compounds of the invention (reaction nos. 5,6,7,9,10,11,12 and 13) inhibit the transcriptase to some degree, the tetramers are particularly effective.
The compoundc; of the invention may be administered in amounts of from about 10 micromoles to about 200 micromoles to inhibit HIV reverse transcriptase and treat HIV.
The compounds also possess antiviral activity against plant-infecting virus, particularly tobacco mosaic virus.
Similar results may be obtained against other viruses which cause necrosis in turnips, cucumber, orchids and in other plants. Such viruses include, but are not limited to, tobacco vein mottling virus, vesicular stomatitis virus, vaccinia virus, turnip necrosis virus, and cymbidium orchid virus.
The compounds may be administered effectively to plants by topical application by abrasion of the leaf surface, aerosol spray, treatment of the soil, spray;ng, or dusting.
An effective antiviral composition may be formed by combining one or more of the compounds of the invention with a suitable carrier material. While the individual stereoisomers are preferred for pharmaceutical use, mixtures of one or more of stereoisomers may be employed in agricultural applications. The active compound may also be administered ~y spraying insect vectors such as aphids, thrips and whiteflies which carry virus to plants. The dosage administer-ed depends upon the severity of the infection.

-52- 1~39~

The compounds of the invention may be applied to plant seeds prior to germination to control viruses contained in the germ plasm. The seeds may be soaked in a solution of polyethylene glycol ("PEG") containing one or more of the compounds. PEG brings the seeds to physiological activity and arrest. The relative concentration of active compound to PEG depends upon the type of seed under treatment.
Plants are effectively treated with an aqueous formulation containing from about 10-1 to about 10-2 M
concentration of active ingredient. The compounds of the invention may be applied at very low concentrations. An effective amount of active ingredient on the plant surface is from about 10-8 to about 10-12 mole per cm2 of plant surface area, with about 10-1~ mole to about 10-12 mole per cm2 being preferred. For the typical tobacco plant of 1,000 cm2, 10-5 M of compound is effective. At this rate, one pound of active ingredient is sufficient to treat 2 x 108 tobacco plants.
For agricultura] application, the compounds are advantageously administered in the form of water-soluble salts, e.g. ammonium or potassium salts. Sodium salts are generally avoided in treating edible plants.
The compounds of the invention are readily dissolved in water, particularly at such low concentrations. Aqueous formulations for agricultural use may optionally contain a sticker and/or a UV-stabilizer. Such agents are well-known to those skilled in the art. ratty acids (1~) are useful as spreader sticker agents. Effective I~V-stabilizers include, for example, p-aminobenzoic acid.

-53- 1~ 3~ 3 Effect of 2',5'Phosphorothioate Oligoadenylates on Tobacco Mosaic Virus (TMV) Replication in Intact Tobacco Plants The effectiveness of the 2',5'-phosphorothioate oligoadenylates against plant virus was demonstrated by infectivity tests on intact Nicotiana glutinosa plants as follows.
Carborundum (400 m~sh) was sprinkled lightly onto leaves. Solutions containing 0.2 micrograms per ml of TMV
and 2 x 10-5 M 2',5'-phosphorothioate oligoadenylate in phosphate buffer were applied onto half-leaves of N.
glutinosa with either a gloved finger or with a pipettor.
The remaining half-leaves were controls (inoculated with the buffer solution containing TMV, but no active compound). The infection was allowed to proceed 48 h under continuous illumination of about 1500 Lx at which time local virus lesions appeared. Inhibition of TMV
replication was calculated as the percent of local lesions produced in 2',5'-phosphorothioate oligoadenylate-treated half-leaves compared to control half-leaves. The data is set forth in Table 6.

6056-5~

13~9~3 Compound3 Percent TMV Inhibition4 s O

ARpARpA 57 ASpAspA 80 ARpASpA 70 ASpARpA 33 pARpA~pA 75 pARpASpA 15 pASpARpA 23 pASpAspA 40 ASpAspAspA
RpAspAspA 80 3 All compounds were added at 2 x 10-5 M in the infecting solution.
4 Inhibition of TMV replication was detected 48 hr after infection and was calculated as the percent of local lesions produced in treated half-leaves of N. glutinosa compared to control half-leaves.

-55- ~ 339'9~

Non-infected plants were treated with 2 x 10-6 M and 2 x 10-5 M of the 2',5'-phosphorothioate core and 5'-monophosphate analogues. No toxicity (chlorosis or necrosis) was observed during the two week period tested.
-5 Of the ten phosphorothioate trimer and tetramer cores and 5'-monophosphates tested, the ~p~p phosphorothioate trimer core inhibited TMV replication to the greatest extent (~0%). Sim;larly, the corresponding tetramer core, SpSpSp, inhibited TMV replication ~y 70%. The RpSpSp tetramer core inhibited TMV replication by 80%. The remarkable inhibition by ASpAspA, ASpAspAspA and ARpASpAspA, as well as the 70% inhibition by ARpASpA, compares with only a 16g inhibition with authentic A3. By introducing the property of chirality, as well as increased metabolic stability, there is a marked increase of the inhibition of TMV replication by the compounds of the invention over 2-5A.
In addition to administration with conventional carriers, the compounds of the present invention may be administered by a variety of specialized oligonucleotide or nucleic acid delivery techniques. 2-5A and its analogues have been successfully encapsulated in unilamellar liposomes and delivered with the aid of monoclonal antibodies to cells (Bayard et al, Eur. J. Biochem.
151:319-325 (1985)). Reconstituted Sendai virus envelopes have been successfully used to deliver RNA and DNA to cells (Arad et al, Biochem. Biophys. Acta 859:88-94 (1986)).
These techniques may be utilized for introduction of the present 2',5'-phosphorothioate oligoadenylates into cells.
It is ~urther contemplated that the compounds of the invention may be administered in the ~orm of prodrugs in which lipophilic groups are attached to, for example, the 5'-terminal hydroxyl group of the core compound.

605~-58 56 iL 3 ~ ~ t Conjugation of 2',5'-Phosphorothioate Tetramer Adenylates Poly(L-lysine) has been described as a versatile membrane carrier for 2-SA and other macro~olecules (Bayard et al, Biochem. 25:3730-3726 (1986)). The tetramer cores and phosphorylated tetramers of the present invention may be conveniently administered in the form of poly(L-lysine) conjugates. The conjugates are formed by introducing two aldehyde functions at the 2' end of the tetramer-by periodate oxidation of the alpha-glycol group of the ribose residue. The resulting aldehyde groups are then randomly coupled to the epsilon-amino groups of lysine residues of poly(L-lysine) by Schiff base formation, and then reduced with sodium cyanoborohydride at pH 8Ø This procedure converts the 2',3'-terminal ribose ring into a morpholine structure. The poly(L-lysine) peptide preferably contains from about 60 to about 70 lysine residues. From about five to about ten of the lysine residues are coupled in this manner to tetramer moieties. The resulting 2',S'-phosphorothioate/poly(L-lysine) conjugates may then be isolated by gel filtration chromatography on a Sephadex G-50 column.
The poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates have the formula:

(fH2)4 (fH2)4 wherein q is an integer ~rom about 60 to about 70 and R is rando~ly R' or -57- ~39'3~3 (~H2)4 -NHCHCO-.

From about five to about ten of the R groups comprise R'.
The R' group has the following formula wherein m is 0,1,2 or 3:

OH<~ ~JN

~m~

~ ~N ~J

~ NH2 ~0- P=S N ~N

1~0 -0_ p=5 ~2 -o~l ~NJ
(CH2)~

~L~ 3~3 .-~3 The conjugates may be advantageously prepared by the procedure of Bayard et al, Biochem.25:3730-3736 (1986):
Example 18 Preparation of Poly(L-lysine)/
2',5'-Phosphorothioate Oligoadenylate Conjugates A 4-microliter aliquot of sodium metaperiodate (0.6 micromole in 0.1 M sodium acetate buffer, pH 4.75) is added to an ice-cold solution of 2',5'-phosphorothioate tetramer adenylate in 400 microliter of distiller water.
The reaction mixture is stirred on ice for 30 min; 400 microliter of poly(L-lysine) (0.14 micromole in 0.2 M
phosphate buffer, pH 8.0) and 200 microliter of sodium cyanoborohydride (20 micromole in 0.2 M phosphate buffer, pH 8.0) are added. The mixture is incubated for 2 h at room temperature and then loaded on a Sephadex G-50 column equilibrated with 0.1 M sodium acetate buffer, pH 4.75.
Each fraction is assayed for its phosphorothioate oligoadenylate/poly(L-lysine) content by the method described by Lowry et al, J. Biol. Chem. 193:265-275 (1951), and by absorbance at 260 nm.
Conjugation of the 2',5'-phosphothioate tetramer to poly(L-lysine) leaves the remaining three 2',5'-linked phosphorothioate adenylic residues intact for optimal ~'~ase L binding and activation.
Liposome Encapsulation of 2',5'-Phosphorothioate Oligoadenylates Encapsulation of the compounds of the present invention comprises another attractive non-disruptive technique for introduction into cells. Liposome encapsulation may be advantageously accomplished according to the technique described by Kondorosi et al., FEBS Lett.
120:37-40 (1980):

133~ 3-~3 Preparation of Large Unilamellar Vesicles (Liposomes) Loaded with 2',5'-Phosphorothioate Oligoadenylates Briefly, a phospholipid mixture from bovine brain (Sigma Chemical Co., Folch fraction III composed of 80-85%
phosphatidylserine with the remaining 15% composed of other brain lipids; 35 mg) is suspended in 5 ml of buffer A [0.1 M NaCl, 2 mM histidine, 2 rnM N-tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid ("TES"), 0.4 mM EDTA (pH 7.4) by vortexing. The suspension is sonicated under nitrogen for 10 minutes at 0~C. The suspension is further incubated for hr at 37~C after adjusting the final concentration of Ca++ to 20 mM by the addition of 125 microliters of 800 mM
CaC12. The resulting precipitate is sedimented by centrifugation (2500 x g, 10 min), ~ortexing and mixing with 100 microliters of 1 x 10-4 M 2',5'-phosphorothioate oligoadenylate, which is dissolved in phosphate-buffered saline. The final concentration of EDTA is then adjusted to 120 mM by the addition of 400 microliters of buffer B
[150 mM EDTA, pH 7.4, 0.1 M NaCl, 2 mM histidine, 2 mM
TES] . Liposomes are formed after incubation of this mixture for 30 minutes at 37~C. The excess of EDTA and non-encapsulated components are removed by passing the 1 iposomes through a Sephadex G-25 column which is equilibrated with phosphate-buffered saline. About 10% of the 2',5'-phosphorothioate oligoadenylate is encapsulated into liposomes by this procedure. The liposome suspension is stable at 4~C for one week following preparation.
Preparation of Reconstituted Sendai Virus E:nvelopes Containing 2',5'-Phosphorothioate Oligoadenylates Reconstituted Sendai virus envelopes may be used as efficient vehicles for the introduction of polynucleotides L3393~3 into cells. Arad et al, Biochimica et Biophysica Acta 859:88-94 (1986) disclose introduction of poly(I) poly(C) into cultured cells by the use of reconstituted Sendai virus envelopes. Fusion of thus-loaded reconstituted Sendai virus envelopes leads to introduction of the enclosed macromolecules into the recipient cell cytoplasm.
Reconstituted Sendai virus envelopes may be obtained by detergent solubilization of intact Sendai virus particles. The reconstituted envelopes are fusogenic vesicles consisting of the viral envelope phospholids and their glycoproteins, devoid of the viral genomic RNA.
Incorporation of the compounds of the present invention into reconstituted Sendai virus envelopes for fusion-mediated micro-injection may be accomplished by following the procedure or Arad et al. Briefly, a pellet of Sendai virus particles (1.5 mg protein) is dissolved in 30 microliters of a solution containing 10% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl (pH 7.4) and 0.1 mM
phenylmethylsulfonyl fluoride (Triton X-lOO:protein ratio, 2:1, w/w). To the clear supernatant obtained after centrifugation, 2',5'-phosphorothioate oligoadenylate dissolved in a solution A (160 mM NaCl, 20 mM Tris-HCl, (pH
7.4)) is added to give a final concentration of active ingredient of 5-20 mg/ml and a final volume of 150 microliters. Triton X-100 is removed from the supernatant by direct addition of 40 mg of SM-2 Bio-Beads. The turbid suspension obtained (containing reconstituted Sendai virus envelopes) is centrifuged at 100,000 x 9 for 1 h. The pellet, containing about 10% of the original viral protein, is then suspended in solution A to give a final protein concentration of 25 micrograms/ml.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference 13~99~3 should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

Claims (46)

1. A compound which is an optical isomer of the formula:

substantially free of contamination by other optical isomers of the same formula, wherein m is zero, 1,2 or 3; n is 1 or 2; and at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
2. A compound according to claim 1 where m is 1.
3. A compound according to claim 1 wherein the internucleotide phosphorothioate group adjacent the 2' terminal adenylate moiety is of the Sp configuration.
4. (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
5. (Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
6. (Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound according to claim 1.
7. 5'-O-phosphoryl-(Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
8. 5'-O-phosphoryl-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
9. 5'-O-phosphoryl-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound according to claim 1.
10. (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
11. The 5'-monophosphate according to claim 10.
12. (Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 10.
13. The 5'-monophosphate according to claim 12.
14. (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
15. The 5'-monophosphate according to claim 14.
16. (Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
17. The 5'-monophosphate according to claim 16.
18. (Sp)-P-thioadenylyl-(2'- 5')-(Rp)-P-thioadenylyl-(2'- 5')-(Sp)-P-thioadenylyl-(2'- 5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
19. The 5'-monophosphate according to claim 18.
20. (Sp)-P-thioadenylyl-(2' - 5')-(Sp)-P-thioadenylyl-(2' - 5')-(Sp)-P-thioadenylyl-(2' - 5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
21. The 5'-monophosphate according to claim 20.
22. An antiviral composition comprising a compound according to claim 1 contained in a reconstituted Sendai virus envelope.
23. An antiviral composition comprising a compound according to claim 1 encapsulated in a liposome.
24. Use of a compound according to any one of claims 1 to 21 for inhibiting viral infection in mammals.
25. A compound according to claim 2 for use in inhibiting viral infection in mammals.
26. A method of inhibiting viral infection in plants comprising administering thereto an antiviral effective amount of a compound according to claim 1.
27. A method of inhibiting viral infection in plants comprising administering thereto an antiviral effective amount of compound according to claim 2.
28. A method of inhibiting viral infection in plants comprising administering thereto an antiviral effective amount of a compound of the following formula, or water-soluble salt thereof, wherein m is zero, 1, 2 or 3 and n is 1 or 2:

,
29. A method according to claim 28, wherein the compound is (Sp) -P-thioadenylyl- ( 2'-5' )-( Sp) -P-thioadenylyl-(2'-5')-adenosine or the 5'-monophosphate thereof.
30. A method according to claim 28, wherein the compound is (Rp)-P-thioadenylyl-(2'-5 ')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
31. A method according to claim 28, wherein the compound is (Rp)-P-thioadenylyl-(2'-5' )-(Rp)-P-thioadenylyl-(2'-5')-adenosine or the 5'-monophosphate thereof.
32. A method according to claim 29 wherein the compound is (Rp) -P-thioadenylyl-(2'-5')- (Sp) -P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine
33. A method according to claim 28 wherein the compound is (Sp) -P-thioadenylyl- (2'-5') -(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
34. A conjugate of poly(L-lysine) and a 2'-5'-phosphorothioate oligoadenylate, said conjugate having the formula wherein q is an integer from about 60 to about 70 and each R
is independently R' or , provided from about five to about ten of the R groups are R', which R' has the following formula wherein m is 0,1,2 or 3:

35. A compound of the formula wherein m is zero, 1, 2 or 3 and n is 2, and water-soluble salts thereof.
36. A compound according to claim 1 wherein m is 3.
37. A method according to claim 26 or 28 for inhibiting tobacco mosaic infection.
38. Use according to claim 24 for inhibiting human immunodeficiency virus.
39. Use according to claim 38 wherein the internucleotide phosphorothioate group adjacent the 2'-terminal adenylate moiety in the compound is of the Sp configuration.
40. Use according to claim 38 wherein the compound is (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, or the 5'-monophosphate thereof.
41. A pharmaceutical composition comprising a pharmaceutical carrier and a compound according to claim 1.
42. A pharmaceutical composition comprising a pharmaceutical carrier and a compound according to claim 35.
43. A conjugate according to claim 34, wherein the 2', 5'- phosphorothioate oligoadenylate from which said conjugate is formed is an optical isomer of the formula substantially free of contamination of other optical isomers of the same formula, where m is zero, 1, 2,, or 3, and at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
44. An antiviral composition comprising a compound according to claim 35 contained in a reconstituted Sendai virus envelope.
45. An antiviral composition comprising a compound according to claim 35 encapsulated in a liposome.
46. A compound according to claim 35 wherein at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
CA000580426A 1987-10-22 1988-10-18 2',5'-phosphorothioate oligoadenylates and antiviral uses thereof Expired - Fee Related CA1339953C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/112,591 US4924624A (en) 1987-10-22 1987-10-22 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US112,591 1987-10-22

Publications (1)

Publication Number Publication Date
CA1339953C true CA1339953C (en) 1998-07-14

Family

ID=22344763

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000580426A Expired - Fee Related CA1339953C (en) 1987-10-22 1988-10-18 2',5'-phosphorothioate oligoadenylates and antiviral uses thereof

Country Status (8)

Country Link
US (3) US4924624A (en)
EP (2) EP0694559B1 (en)
JP (1) JP2733777B2 (en)
AT (2) ATE135579T1 (en)
AU (1) AU2628088A (en)
CA (1) CA1339953C (en)
DE (2) DE3856326T2 (en)
WO (1) WO1989003683A1 (en)

Families Citing this family (836)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JP2976436B2 (en) * 1988-04-27 1999-11-10 味の素株式会社 Novel oligoribonucleotide derivatives and use as antiviral agents
DK0497875T3 (en) 1989-10-24 2000-07-03 Gilead Sciences Inc 2'-modified oligonucleotides
US5635488A (en) * 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5587361A (en) * 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5620963A (en) * 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US6446032B1 (en) * 1990-09-21 2002-09-03 Massachusetts Institute Of Technology Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove
US6041910A (en) * 1997-09-22 2000-03-28 Jervis B. Webb Company Baggage pusher device and system
GB9111967D0 (en) * 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5571799A (en) * 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
WO1993003733A1 (en) * 1991-08-12 1993-03-04 Basco, Ltd. Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5599797A (en) * 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5607923A (en) * 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5661134A (en) * 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5654284A (en) * 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
CA2130926C (en) * 1992-03-12 2003-10-21 Robert J. Suhadolnik Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE69433036T2 (en) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
US7276335B1 (en) * 1993-09-29 2007-10-02 Massachusetts Institute Of Technology Designing compounds specifically inhibiting ribonucleic acid function
WO1996008256A1 (en) * 1994-09-14 1996-03-21 Temple University - Of The Commonwealth System Of Higher Education 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
WO2005121371A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5955446A (en) * 1997-01-16 1999-09-21 Pentose Pharmaceuticals, Inc. Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
US6468991B1 (en) 1997-01-16 2002-10-22 Cyclis Pharmaceuticals, Inc. Method of treating rhinoviral infections
US6281201B1 (en) 1997-06-12 2001-08-28 Temple University- Of The Commonwealth System Of Higher Education Base-modified derivatives of 2′,5′-oligoadenylate and antiviral uses thereof
US6362171B1 (en) 1997-06-12 2002-03-26 Temple University-Of The Commonwealth System Of Higher Education Aminoaklanoyl-linked conjugates of 2′,5′-oligoadenylate and antiviral uses thereof
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999005160A2 (en) * 1997-07-25 1999-02-04 Hybridon, Inc. Oligonuclotides having 3' terminal stereospecific phosphorothioates
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US7321828B2 (en) * 1998-04-13 2008-01-22 Isis Pharmaceuticals, Inc. System of components for preparing oligonucleotides
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
AU745880B2 (en) * 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
JP2002515514A (en) 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for local delivery of oligonucleotides
US6461815B1 (en) 1998-05-22 2002-10-08 North Carolina State University Antibacterial agents and methods of screening for the same
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en) 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
BR9914465A (en) * 1998-09-29 2001-10-09 Gamida Cell Ltd Methods to control the proliferation and differentiation of stem cells and progenitor cells and a pharmaceutical composition to induce differentiation in a cell population
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) * 1999-01-20 2000-10-03 Isis Pharmaceuticals, Inc. Fluorescence based nuclease assay
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
DE19940748A1 (en) * 1999-08-27 2001-03-01 Hugo Seinfeld Medicaments containing xenogenic oligo- and / or polyribonucleotides
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
ATE452906T1 (en) * 2000-04-13 2010-01-15 Thomas N Wight THERAPEUTIC SUMMARY AND METHODS FOR MODULATING V3, AN ISOFORM OF VERSICAN
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
CA2425779C (en) 2000-10-12 2013-08-06 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
KR20020069627A (en) * 2001-02-27 2002-09-05 동부한농화학 주식회사 Phosphorothioate oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof
JP2004533815A (en) 2001-03-14 2004-11-11 ミリアド・ジェネティックス・インコーポレイテッド TSG101-GAG interaction and use thereof
ATE522623T1 (en) 2001-06-20 2011-09-15 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS
EP1404698A4 (en) 2001-06-21 2004-12-22 Isis Pharmaceuticals Inc Antisense modulation of superoxide dismutase 1, soluble expression
DE10133858A1 (en) 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetic double-stranded oligonucleotides for targeted inhibition of gene expression
US6822088B2 (en) 2001-07-17 2004-11-23 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides on solid support
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
CA2455424A1 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
JP2005525095A (en) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
AU2003231912A1 (en) * 2002-06-12 2003-12-31 Tel Aviv Medical Center Research Development Fund Methods of detecting and treating prostate cancer
US20040092470A1 (en) * 2002-06-18 2004-05-13 Leonard Sherry A. Dry powder oligonucleotide formualtion, preparation and its uses
EP2116604A1 (en) 2002-08-05 2009-11-11 University of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
EP1546170A4 (en) 2002-09-20 2007-08-29 Univ Yale Riboswitches, methods for their use, and compositions for use with riboswitches
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
JP2006515318A (en) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション Specifically associated cancer-related gene, polypeptide encoded thereby and method of use thereof
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
SI1569695T1 (en) 2002-11-13 2013-08-30 Genzyme Corporation Antisense modulation of apolipoprotein b expression
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
ES2392511T3 (en) 2002-11-15 2012-12-11 Musc Foundation For Research Development Complement modulators targets on complement receptor 2
CA2506127C (en) 2002-11-15 2013-07-09 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP1583843B1 (en) 2002-12-20 2018-07-18 QIAGEN GmbH Single primer whole genome amplification
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
CA2522184A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Of New York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
BRPI0410886A (en) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide
DK2336317T3 (en) 2003-06-13 2019-12-16 Alnylam Europe Ag Double-stranded ribonucleic acid with increased efficiency in an organism
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
EP1677822B1 (en) * 2003-09-18 2014-04-23 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
KR100750788B1 (en) 2003-09-18 2007-08-20 아이시스 파마수티컬즈 인코포레이티드 4 MODULATION OF eIF4E EXPRESSION
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005056571A1 (en) * 2003-12-05 2005-06-23 Biovitrum Ab Improved synthesis of 2-substituted adenosines
EP2363480A3 (en) 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20060147946A1 (en) * 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
US7842459B2 (en) 2004-01-27 2010-11-30 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en) 2004-03-15 2005-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of rna by rnase h
KR101147147B1 (en) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Modified polynucleotides for reducing off-target effects in rna interference
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US20050267300A1 (en) 2004-04-05 2005-12-01 Muthiah Manoharan Processes and reagents for oligonucleotide synthesis and purification
US20050260755A1 (en) * 2004-04-06 2005-11-24 Isis Pharmaceuticals, Inc. Sequential delivery of oligomeric compounds
EP3034510A1 (en) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
JP2008500064A (en) 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション Variable lymphocyte receptor, related polypeptides and nucleic acids, and uses thereof
EP1766052A4 (en) * 2004-06-03 2009-12-16 Isis Pharmaceuticals Inc Chimeric gapped oligomeric compositions
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
TR201907874T4 (en) * 2004-09-23 2019-06-21 Arc Medical Devices Inc Pharmaceutical compositions and methods for inhibiting fibrous adhesions or inflammatory diseases using low sulphate fucans.
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US20060166234A1 (en) 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP1863908B1 (en) * 2005-04-01 2010-11-17 Qiagen GmbH Reverse transcription and amplification of rna with simultaneous degradation of dna
JP5329949B2 (en) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
JP5383186B2 (en) 2005-07-07 2014-01-08 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド Nucleic acid agents that down-regulate H19 and methods of using the same
MY144014A (en) 2005-08-11 2011-07-29 Synthetic Genomics Inc Method for in vitro recombination
KR20080036646A (en) 2005-08-17 2008-04-28 메덱시스 에스.에이. Composition and method for determination of ck19 expression
CA2620856C (en) 2005-08-29 2017-11-28 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
AU2006304321B2 (en) 2005-10-14 2012-10-04 Musc Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
AU2006305886C1 (en) 2005-10-28 2011-03-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
AU2006311730B2 (en) 2005-11-09 2010-12-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
EP1966377A2 (en) 2005-11-21 2008-09-10 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
JP2009524411A (en) * 2005-12-21 2009-07-02 イェール ユニバーシティー Methods and compositions related to the regulation of riboswitches
JP5713377B2 (en) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
WO2007080597A2 (en) 2006-01-16 2007-07-19 Compugen Ltd. Polynucleotide and polypeptide sequences and methods for diagnosis
KR101304071B1 (en) * 2006-01-27 2013-09-06 아이시스 파마수티컬즈 인코포레이티드 6-modified bicyclic nucleic acid analogs
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
JP5213723B2 (en) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ, インコーポレーテッド Oligomer compounds and compositions for use in modulating microRNA
SG170780A1 (en) 2006-03-31 2011-05-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 gene
DE102006020885A1 (en) * 2006-05-05 2007-11-08 Qiagen Gmbh Inserting a tag sequence into a nucleic acid comprises using an anchor oligonucleotide comprising a hybridizing anchor sequence and a nonhybridizing tag-template sequence
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
AU2007249329C1 (en) 2006-05-11 2011-03-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
WO2007137156A2 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
WO2007137220A2 (en) 2006-05-22 2007-11-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
JP2010502752A (en) * 2006-09-11 2010-01-28 イェール ユニバーシティー Lysine riboswitch, structure-based compound design using lysine riboswitch, and methods and compositions for use with lysine riboswitch
WO2008036933A2 (en) 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
CA2663601C (en) 2006-09-22 2014-11-25 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
CA2665225C (en) 2006-10-03 2015-06-30 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
EP2081596A4 (en) 2006-10-06 2010-07-21 Univ Utah Res Found Method of detecting ocular diseases and pathologic conditions and treatment of same
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
JP2010512327A (en) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Compositions and methods for the treatment of pathological angiogenesis and vascular permeability
EP2913341A1 (en) 2006-12-22 2015-09-02 University of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2111450A2 (en) * 2007-01-16 2009-10-28 Yissum Research Development Company of the Hebrew University of Jerusalem Nucleic acid constructs and methods for specific silencing of h19
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
KR20100015757A (en) 2007-03-22 2010-02-12 예일 유니버시티 Methods and compositions related to riboswitches that control alternative splicing
PE20090064A1 (en) 2007-03-26 2009-03-02 Novartis Ag DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AP2014007971A0 (en) 2007-03-29 2014-09-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
EP2639316A1 (en) 2007-05-11 2013-09-18 The Johns Hopkins University Biomarkers for melanoma
WO2008150884A1 (en) * 2007-05-29 2008-12-11 Yale University Methods and compositions related to riboswitches that control alternative splicing and rna processing
CN101849020A (en) 2007-05-29 2010-09-29 耶鲁大学 The method and composition of riboswitch and use riboswitch
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2160464B1 (en) * 2007-05-30 2014-05-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) * 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CN103215269B (en) 2007-07-05 2015-01-21 诺瓦提斯公司 Dsrna for treating viral infection
ES2439591T3 (en) 2007-08-15 2014-01-23 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
CA2704729C (en) 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
ES2719728T3 (en) 2007-09-04 2019-07-12 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a pharmacological target to produce drugs and biological agents
WO2009039466A1 (en) 2007-09-20 2009-03-26 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) * 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
CA2700953A1 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
US20110152346A1 (en) * 2007-11-05 2011-06-23 Baltic Technology Development Ltd. Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
EP2222851B1 (en) * 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation of cd40 expression
US8546556B2 (en) * 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009076400A2 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009100320A2 (en) * 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
CN104975020B (en) * 2008-02-11 2020-01-17 菲奥医药公司 Modified RNAi polynucleotides and uses thereof
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009111658A2 (en) 2008-03-05 2009-09-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 and vegf genes
EP2282744B1 (en) * 2008-03-21 2018-01-17 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009124238A1 (en) * 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
CA2720675C (en) 2008-04-18 2019-08-27 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2009134917A2 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
AU2009272841A1 (en) * 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of TGF-beta receptor genes
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2323667A4 (en) * 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc Modulation of transthyretin expression for the treatment of cns related disorders
AU2009275387B2 (en) 2008-08-25 2010-07-08 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2331690B1 (en) 2008-09-02 2016-01-13 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of mutant egfr gene
CN102405286A (en) 2008-09-22 2012-04-04 阿克赛医药公司 Reduced size self-delivering rnai compounds
DK2361256T3 (en) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nucleic acid analogues
DK2356129T3 (en) * 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituted alpha-L bicyclic nucleosides
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ, インコーポレイテッド Lipid formulation composition and method for inhibiting expression of serum amyloid A gene
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN102245186B (en) 2008-10-15 2014-08-27 Isis制药公司 Modulation of factor 11 expression
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
JP5763539B2 (en) 2008-10-24 2015-08-12 アイシス ファーマシューティカルズ, インコーポレーテッド 5 'and 2' bis-substituted nucleosides and oligomeric compounds produced therefrom
WO2010055041A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of factor vii genes
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
KR101692880B1 (en) * 2008-11-24 2017-01-04 노오쓰웨스턴 유니버시티 Polyvalent rna-nanoparticle compositions
WO2010061393A1 (en) 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
US20110237649A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CN102317458B (en) 2008-12-04 2018-01-02 库尔纳公司 Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
MX358603B (en) 2008-12-04 2018-08-28 Curna Inc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene.
ES2442168T3 (en) 2008-12-05 2014-02-10 Yeda Research And Development Co. Ltd. Diagnostic methods of motor neuron diseases
JP5855462B2 (en) 2008-12-10 2016-02-09 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. DsRNA compositions targeting GNAQ and methods for inhibiting expression
WO2010080554A1 (en) 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
CN102307470B (en) * 2009-01-08 2015-05-20 西北大学 Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (en) * 2009-01-15 2015-08-25 삼성전자주식회사 Toner for electrophotographic and process for preparing the same
CA3036963A1 (en) 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
AU2010211133A1 (en) * 2009-02-03 2011-07-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of PTP1B genes
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
CN102439149B (en) 2009-02-12 2018-01-02 库尔纳公司 By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
PL2396038T3 (en) 2009-02-12 2016-05-31 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
EP2403946A4 (en) 2009-03-04 2012-11-14 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
EP2419535B1 (en) 2009-04-15 2022-08-17 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
EP3524275A1 (en) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Innate immune supression enables repeated delivery of long rna molecules
WO2010127195A2 (en) 2009-05-01 2010-11-04 Curna, Inc. Antisense oligonucleotides of hemoglobins
WO2010129687A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc Methods of delivering oligonucleotides to immune cells
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
CN106237345A (en) 2009-05-06 2016-12-21 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
US20120046236A1 (en) 2009-05-06 2012-02-23 Opko Curna Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
EP2429657A2 (en) * 2009-05-15 2012-03-21 F. Hoffmann-La Roche AG Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
EP2430161A1 (en) 2009-05-15 2012-03-21 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
JP5922017B2 (en) 2009-05-18 2016-05-24 クルナ・インコーポレーテッド Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor
JP2012527248A (en) 2009-05-22 2012-11-08 クルナ・インコーポレーテッド Treatment of TFE3 and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcripts against transcription factor E3 (TFE3)
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
JP5960049B2 (en) 2009-05-28 2016-08-02 クルナ・インコーポレーテッド Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes
NZ622843A (en) 2009-06-10 2015-10-30 Tekmira Pharmaceuticals Corp Improved lipid formulation
CN102612560B (en) 2009-06-16 2017-10-17 库尔纳公司 By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1)
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US20100331397A1 (en) * 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US9512164B2 (en) 2009-07-07 2016-12-06 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en) 2009-08-17 2012-06-21 Yale University Methylation biomarkers and methods of use
EP2470657B1 (en) 2009-08-25 2019-10-23 CuRNA, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
ES2599076T3 (en) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutant and methods of use thereof
WO2011044902A1 (en) 2009-10-13 2011-04-21 Aarhus Universitet Tff3 hypomethylation as a novel biomarker for prostate cancer
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
WO2011045796A1 (en) 2009-10-14 2011-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056687A2 (en) 2009-10-27 2011-05-12 Swift Biosciences, Inc. Polynucleotide primers and probes
AU2010313154B2 (en) 2009-10-30 2016-05-12 Northwestern University Templated nanoconjugates
US20130084565A1 (en) 2009-11-03 2013-04-04 University Of Virginia Patent Foundation Versatile, visible method for detecting polymeric analytes
US20110112176A1 (en) * 2009-11-09 2011-05-12 John Frederick Boylan Compositions and methods for inhibiting expression of kif10 genes
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
CN107312777B (en) 2009-11-13 2020-11-13 萨雷普塔治疗公司 Antisense antiviral compounds and methods of treating influenza virus infection
WO2011063403A1 (en) 2009-11-23 2011-05-26 Swift Biosciences, Inc. Devices to extend single stranded target molecules
MX2012006072A (en) 2009-11-30 2012-07-23 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ).
KR101823702B1 (en) 2009-12-16 2018-01-30 큐알엔에이, 인크. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー,インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63)
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
NO2521784T3 (en) 2010-01-04 2018-05-05
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
WO2011088076A2 (en) 2010-01-12 2011-07-21 Yale University Structured rna motifs and compounds and methods for their use
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
CA2824843A1 (en) 2010-02-04 2011-08-11 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2011095174A1 (en) 2010-02-08 2011-08-11 Aarhus Universitet Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum
EP2539452B1 (en) 2010-02-22 2016-07-27 CuRNA, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
BR112012020373A8 (en) 2010-02-23 2018-01-02 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
NZ601784A (en) 2010-03-08 2014-08-29 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US8906875B2 (en) 2010-03-12 2014-12-09 The Brigham And Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
KR101852210B1 (en) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 Rna interference in dermal and fibrotic indications
RU2615143C2 (en) 2010-03-24 2017-04-04 Адвирна Self-delivered rnai compounds of reduced size
US8889350B2 (en) 2010-03-26 2014-11-18 Swift Biosciences, Inc. Methods and compositions for isolating polynucleotides
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
EP3517613A1 (en) 2010-04-09 2019-07-31 CuRNA, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US20110269194A1 (en) 2010-04-20 2011-11-03 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US9127033B2 (en) 2010-04-28 2015-09-08 Isis Pharmaceuticals, Inc. 5′ modified nucleosides and oligomeric compounds prepared therefrom
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
JP5896175B2 (en) 2010-04-29 2016-03-30 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Regulation of transthyretin expression
CN102958941A (en) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 Compositions and methods for the diagnosis and treatment of tumor
KR20130101442A (en) 2010-05-03 2013-09-13 큐알엔에이, 인크. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CA2805086C (en) 2010-05-13 2020-10-20 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
CA2801066C (en) 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en) 2010-06-11 2017-05-02 Vanderbilt University Multiplexed interferometric detection system and method
WO2011163466A1 (en) 2010-06-23 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (nrg-1)
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
US20130143955A1 (en) 2010-08-09 2013-06-06 Yale University Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
US20130210901A1 (en) 2010-09-20 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
WO2012052872A2 (en) 2010-10-17 2012-04-26 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
EP2851426B1 (en) 2010-10-18 2018-08-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of RRM2 genes
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
EP2633052B1 (en) 2010-10-27 2018-04-11 CuRNA, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
CN110123830A (en) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
JP6336755B2 (en) 2010-11-12 2018-06-06 ザ ジェネラル ホスピタル コーポレイション Non-coding RNA related to polycomb
JP6126009B2 (en) 2010-11-17 2017-05-10 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Regulation of α-synuclein expression
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9193973B2 (en) 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
CN103391777A (en) 2011-02-02 2013-11-13 普林斯顿大学理事会 Sirtuin modulators as virus production modulators
TWI593416B (en) 2011-02-02 2017-08-01 艾克厘德製藥公司 Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
US9562853B2 (en) 2011-02-22 2017-02-07 Vanderbilt University Nonaqueous backscattering interferometric methods
CA2831284C (en) 2011-03-29 2023-12-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of tmprss6 gene
JP2014511694A (en) 2011-04-03 2014-05-19 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル Efficient in vivo protein expression using modified RNA (MOD-RNA)
AU2012241373B2 (en) 2011-04-15 2016-06-09 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
CN112961855A (en) 2011-06-21 2021-06-15 阿尔尼拉姆医药品有限公司 Angiopoietin-like 3(ANGPTL3) iRNA compositions and methods of use thereof
US9068184B2 (en) 2011-06-21 2015-06-30 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein C (PROC) genes
MX344807B (en) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes.
EP3366312A1 (en) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: compositions of matter and methods of treatment
BR112013031021A2 (en) 2011-06-30 2018-10-09 Arrowhead Res Corp compositions and methods for inhibiting hepatitis b virus gene expression
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US20140328811A1 (en) 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
CA3107434C (en) 2011-08-04 2023-06-06 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
MX362812B (en) 2011-09-13 2019-02-13 Monsanto Technology Llc Methods and compositions for weed control.
BR112014005958A2 (en) 2011-09-13 2020-10-13 Monsanto Technology Llc agricultural chemical methods and compositions for plant control, method of reducing expression of an accase gene in a plant, microbial expression cassette, method for making a polynucleotide, method of identifying polynucleotides useful in modulating expression of the accase gene and herbicidal composition
BR112014005978A8 (en) 2011-09-13 2017-09-12 Monsanto Technology Llc AGRICULTURAL CHEMICAL METHODS AND COMPOSITIONS FOR PLANT CONTROL, METHOD FOR REDUCING EXPRESSION OF A GS GENE IN A PLANT, MICROBIAL EXPRESSION CASSETTE, METHOD FOR MAKING A POLYNUCLEOTIDE AND METHOD FOR IDENTIFYING POLYNUCLEOTIDES USEFUL IN MODULATING GS GENE EXPRESSION
MX350771B (en) 2011-09-13 2017-09-15 Monsanto Technology Llc Methods and compositions for weed control.
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
US9580713B2 (en) 2011-09-17 2017-02-28 Yale University Fluoride-responsive riboswitches, fluoride transporters, and methods of use
CA2851280C (en) 2011-10-11 2021-05-18 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
MX2014004022A (en) 2011-10-14 2014-04-30 Genentech Inc ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
FR2981650B1 (en) * 2011-10-24 2013-12-27 Univ Paris Curie NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF VIRAL INFECTION AND METHOD OF EVALUATING SENSITIVITY TO TREATMENT
EP2771464B1 (en) 2011-10-27 2018-03-21 Yeda Research and Development Co. Ltd. Methods of treating cancer
US10557136B2 (en) 2011-12-12 2020-02-11 Oncolmmunin Inc. In vivo delivery of oligonucleotides
CN104185681A (en) 2012-02-01 2014-12-03 卡姆普根有限公司 C10RF32 antibodies, and uses thereof for treatment of cancer
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
WO2013124816A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
US10034902B2 (en) 2012-02-22 2018-07-31 Exostem Biotec Ltd. MicroRNAs for the generation of astrocytes
EP2825672B1 (en) 2012-03-13 2019-02-13 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
JP2015518485A (en) 2012-04-20 2015-07-02 アプタミアール セラピューティクス インコーポレイテッド Thermogenic miRNA regulator
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP3597741A1 (en) 2012-04-27 2020-01-22 Duke University Genetic correction of mutated genes
US9273949B2 (en) 2012-05-11 2016-03-01 Vanderbilt University Backscattering interferometric methods
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
JP2015523854A (en) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating SMN gene family expression
WO2013175480A1 (en) 2012-05-24 2013-11-28 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
US20140038182A1 (en) 2012-07-17 2014-02-06 Dna Logix, Inc. Cooperative primers, probes, and applications thereof
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
CA2880833A1 (en) 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
EP2885312A4 (en) 2012-08-15 2016-01-20 Isis Pharmaceuticals Inc Method of preparing oligomeric compounds using modified capping protocols
CA2880869A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2014062989A2 (en) 2012-10-18 2014-04-24 Monsanto Technology Llc Methods and compositions for plant pest control
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
EP2941487A2 (en) 2013-01-01 2015-11-11 A.B. Seeds Ltd. ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
DK2951191T3 (en) 2013-01-31 2019-01-14 Ionis Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
EP3366772A1 (en) * 2013-02-22 2018-08-29 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
UA121846C2 (en) 2013-03-13 2020-08-10 Монсанто Текнолоджи Ллс METHOD AND HERBICIDAL COMPOSITION FOR CONTROL OF PLANT SPECIES OF THE GENUS LOLIUM
CN105074008A (en) 2013-03-13 2015-11-18 孟山都技术有限公司 Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
NZ712336A (en) 2013-03-14 2020-03-27 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
JP2016522679A (en) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing with the CRISPR / Cas system
BR112015027321A8 (en) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
IL293657A (en) 2013-05-22 2022-08-01 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
PT2999785T (en) 2013-05-22 2018-07-09 Alnylam Pharmaceuticals Inc Serpina1 irna compositions and methods of use thereof
US20160113911A1 (en) 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
DK3007704T3 (en) 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Combination therapy for acromegaly
UA122662C2 (en) 2013-07-19 2020-12-28 Монсанто Текнолоджі Ллс Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2014306271A1 (en) 2013-08-08 2016-03-24 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
WO2015048558A1 (en) 2013-09-30 2015-04-02 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
CN105793423A (en) 2013-10-02 2016-07-20 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of the LECT2 gene
KR102298475B1 (en) 2013-10-04 2021-09-06 노파르티스 아게 3' END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
SG10201910929QA (en) 2013-10-04 2020-01-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene
JP6546161B2 (en) 2013-10-04 2019-07-17 ノバルティス アーゲー Organic compounds for treating hepatitis B virus
EP3055426B1 (en) 2013-10-09 2019-06-19 The United States of America as represented by The Secretary Department of Health and Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en) 2013-10-21 2015-04-30 Isis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
CA2928779A1 (en) 2013-10-21 2015-04-30 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US9540642B2 (en) 2013-11-04 2017-01-10 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods for controlling arthropod parasite and pest infestations
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
JP6772062B2 (en) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. Cancer immunotherapy
CN112107693B (en) 2013-12-03 2023-05-26 西北大学 Liposome particles, method for preparing said liposome particles and use thereof
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
UA119253C2 (en) 2013-12-10 2019-05-27 Біолоджикс, Інк. Compositions and methods for virus control in varroa mite and bees
JP6710638B2 (en) 2013-12-12 2020-06-17 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Complement component iRNA composition and method of using the same
EP3865144A1 (en) 2013-12-20 2021-08-18 The General Hospital Corporation Methods and assays relating to circulating tumor cells
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
US10125365B2 (en) 2014-02-05 2018-11-13 Yeda Research And Development Co. Ltd. Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
KR20230152154A (en) 2014-02-11 2023-11-02 알닐람 파마슈티칼스 인코포레이티드 KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
PL3119888T3 (en) 2014-03-19 2021-12-20 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
PL3757214T3 (en) 2014-04-01 2022-09-12 Biogen Ma Inc. Compositions for modulating sod-1 expression
CN110506752B (en) 2014-04-01 2022-02-18 孟山都技术公司 Compositions and methods for controlling insect pests
HUE056155T2 (en) 2014-04-09 2022-01-28 Scripps Research Inst Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
ES2745825T3 (en) 2014-05-01 2020-03-03 Ionis Pharmaceuticals Inc Compositions and methods for modulating expression of complement factor B
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
SG10202104570TA (en) 2014-05-22 2021-06-29 Alnylam Pharmaceuticals Inc Angiotensinogen (agt) irna compositions and methods of use thereof
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
ES2908962T3 (en) 2014-06-10 2022-05-04 Univ Erasmus Med Ct Rotterdam Antisense oligonucleotides useful in the treatment of Pompe disease
CA2953347A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP3161138A4 (en) 2014-06-25 2017-12-06 Monsanto Technology LLC Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
JP6671363B2 (en) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Isolated polypeptide of CD44 and uses thereof
US9951327B1 (en) 2014-07-17 2018-04-24 Integrated Dna Technologies, Inc. Efficient and rapid method for assembling and cloning double-stranded DNA fragments
RU2754955C2 (en) 2014-07-29 2021-09-08 Монсанто Текнолоджи Ллс Compositions and methods for combating insect pests
BR112017001860A2 (en) 2014-07-31 2018-02-27 Uab Research Foundation synthetic peptide, pharmaceutical composition, methods, dosage regimen, and monoclonal antibody
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10060921B2 (en) 2014-08-29 2018-08-28 Alnylam Pharmaceuticals, Inc. Methods of treating transthyretin (TTR) mediated amyloidosis
CA2959386A1 (en) 2014-08-29 2016-03-03 Lee Adam Wheeler Methods and compositions for the treatment of cancer
KR102506169B1 (en) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016049512A1 (en) 2014-09-26 2016-03-31 University Of Massachusetts Rna-modulating agents
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016094845A2 (en) 2014-12-12 2016-06-16 Woolf Tod M Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US10538763B2 (en) 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
RU2723049C2 (en) 2015-01-22 2020-06-08 Монсанто Текнолоджи Ллс Compositions and methods for controlling leptinotarsa
JP2018506715A (en) 2015-01-23 2018-03-08 ヴァンダービルト ユニバーシティー Robust interferometer and method of use
JP6929791B2 (en) 2015-02-09 2021-09-01 デューク ユニバーシティ Compositions and methods for epigenome editing
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262181A4 (en) 2015-02-23 2018-11-21 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
EP3262173A2 (en) 2015-02-23 2018-01-03 Crispr Therapeutics AG Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
US10781445B2 (en) 2015-03-11 2020-09-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
KR20180020125A (en) 2015-03-27 2018-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Modified T cells and methods for their manufacture and use
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US10907152B2 (en) 2015-05-04 2021-02-02 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
WO2016181393A1 (en) 2015-05-11 2016-11-17 Yeda Research And Development Co. Ltd. Citrin inhibitors for the treatment of cancer
CN107750125A (en) 2015-06-02 2018-03-02 孟山都技术有限公司 For by the composition and method in delivery of polynucleotides to plant
US10655136B2 (en) 2015-06-03 2020-05-19 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
CN108135923B (en) 2015-07-06 2021-03-02 菲奥医药公司 Nucleic acid molecules targeting superoxide dismutase 1(SOD1)
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
WO2017019918A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
EP3331546B1 (en) 2015-08-03 2023-10-04 Biokine Therapeutics Ltd. Cxcr4 inhibitor for the treatment of cancer
US20180237774A1 (en) 2015-08-04 2018-08-23 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
WO2017027350A2 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
CN108368507B (en) 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof
WO2017064546A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
WO2017053781A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
CA3002744A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2017075038A1 (en) 2015-10-26 2017-05-04 Rana Therapeutics, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2017072590A1 (en) 2015-10-28 2017-05-04 Crispr Therapeutics Ag Materials and methods for treatment of duchenne muscular dystrophy
AU2016344399B2 (en) 2015-10-30 2019-03-28 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
CN109328231A (en) 2015-11-06 2019-02-12 克里斯普治疗股份公司 For treating the material and method of 1A type glycogen storage disease
EP3373939A4 (en) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
US11851653B2 (en) 2015-12-01 2023-12-26 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
US10993995B2 (en) 2015-12-07 2021-05-04 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
CA3009308A1 (en) 2015-12-23 2017-06-29 Chad Albert COWAN Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
EP3408649B1 (en) 2016-01-29 2023-06-14 Vanderbilt University Free-solution response function interferometry
US20190038771A1 (en) 2016-02-02 2019-02-07 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
JP2019509721A (en) 2016-02-04 2019-04-11 キュリス,インコーポレイテッド Mutant smoothened and method of using the same
EP3416689B1 (en) 2016-02-18 2023-01-18 CRISPR Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
EP3419665A4 (en) 2016-02-25 2019-10-16 The Brigham and Women's Hospital, Inc. Treatment methods for fibrosis targeting smoc2
US10961271B2 (en) 2016-03-16 2021-03-30 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
WO2017158422A1 (en) 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
US10577607B2 (en) 2016-03-16 2020-03-03 Ionis Pharmaceuticals, Inc. Modulation of DYRK1B expression
EP3430137A4 (en) 2016-03-18 2019-11-06 Caris Science, Inc. Oligonucleotide probes and uses thereof
IL262416B2 (en) 2016-04-18 2024-02-01 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
MA45295A (en) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
AU2017271579B2 (en) 2016-05-25 2023-10-19 Caris Science, Inc. Oligonucleotide probes and uses thereof
US20190256845A1 (en) 2016-06-10 2019-08-22 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
US20190218257A1 (en) 2016-06-24 2019-07-18 The Scripps Research Institute Novel nucleoside triphosphate transporter and uses thereof
AU2017290614C1 (en) 2016-06-29 2024-01-18 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
AU2017292169B2 (en) 2016-07-06 2021-12-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
CA3030701A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
EP3487992A4 (en) 2016-07-21 2020-03-18 Maxcyte, Inc. Methods and compositions for modifying genomic dna
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
JOP20170161A1 (en) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc RNAi Agents for Hepatitis B Virus Infection
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
PT3506909T (en) 2016-09-02 2022-08-16 Dicerna Pharmaceuticals Inc 4'-phosphate analogs and oligonucleotides comprising the same
WO2018055577A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
EP3522898A4 (en) 2016-10-06 2020-05-27 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (en) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
EP3548620A4 (en) 2016-12-02 2020-07-22 Cold Spring Harbor Laboratory Modulation of lnc05 expression
JP7206214B2 (en) 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) Methods for exogenous drug activation of chemo-inducible signaling complexes expressed in engineered cells in vitro and in vivo
TWI790217B (en) 2016-12-16 2023-01-21 美商阿尼拉製藥公司 METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
AU2018210364B2 (en) 2017-01-23 2022-03-17 Regeneron Pharmaceuticals, Inc. HSD17B13 variants and uses thereof
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
WO2018154387A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018154462A2 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
US20200040061A1 (en) 2017-02-22 2020-02-06 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
US20180284123A1 (en) 2017-03-30 2018-10-04 California Institute Of Technology Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
CN110913898A (en) 2017-04-18 2020-03-24 阿尔尼拉姆医药品有限公司 Methods of treating subjects having Hepatitis B Virus (HBV) infection
EP3612546B1 (en) 2017-04-20 2022-07-13 Synthena AG Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018193428A1 (en) 2017-04-20 2018-10-25 Synthena Ag Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
EP3612232A1 (en) 2017-04-21 2020-02-26 The Broad Institute, Inc. Targeted delivery to beta cells
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
TWI821192B (en) 2017-07-11 2023-11-11 美商新索思股份有限公司 Incorporation of unnatural nucleotides and methods thereof
JP2020526558A (en) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ Common and direct methods for preparing oligonucleotide functionalized metal-organic framework nanoparticles
WO2019014530A1 (en) 2017-07-13 2019-01-17 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
KR20200035092A (en) 2017-08-03 2020-04-01 신톡스, 인크. Cytokine conjugates for the treatment of autoimmune diseases
US11197884B2 (en) 2017-08-18 2021-12-14 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. Modulators of smad7 expression
WO2019060442A1 (en) 2017-09-19 2019-03-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
MX2020004043A (en) 2017-10-17 2021-05-27 Crispr Therapeutics Ag Compositions and methods for gene editing for hemophilia a.
US20210180091A1 (en) 2017-10-26 2021-06-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
MA50578A (en) 2017-11-09 2021-09-15 Vertex Pharma CRISPR / CAS SYSTEMS FOR THE TREATMENT OF DMD
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
EP3710587A1 (en) 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
CA3082450A1 (en) 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materials and methods for treatment of autosomal dominant retinitis pigmentosa
US20200384033A1 (en) 2017-12-05 2020-12-10 Vertex Pharmaceuticals Incorporated Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
CA3084825A1 (en) 2017-12-14 2019-06-20 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and their use in genome editing and other applications
MX2020006012A (en) 2017-12-18 2020-09-14 Alnylam Pharmaceuticals Inc High mobility group box-1 (hmgb1) irna compositions and methods of use thereof.
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
WO2019123429A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
MA51637A (en) 2018-01-12 2020-11-18 Bayer Healthcare Llc COMPOSITIONS AND METHODS FOR TARGETING GENE EDITING OF TRANSFERRIN
JP2021511072A (en) 2018-01-15 2021-05-06 アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. DNM2 expression modulator
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
MA51788A (en) 2018-02-05 2020-12-16 Vertex Pharma SUBSTANCES AND METHODS FOR TREATING HEMOGLOBINOPATHIES
WO2019155465A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
WO2019161310A1 (en) 2018-02-16 2019-08-22 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing by targeting fibrinogen-alpha
CN112004547A (en) 2018-02-26 2020-11-27 新索思股份有限公司 IL-15 conjugates and uses thereof
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein
TW202000199A (en) 2018-03-02 2020-01-01 美商Ionis製藥公司 Modulators of IRF4 expression
WO2019170731A1 (en) 2018-03-07 2019-09-12 Sanofi Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same
EP3768834A1 (en) 2018-03-19 2021-01-27 CRISPR Therapeutics AG Novel rna-programmable endonuclease systems and uses thereof
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
CA3095545A1 (en) 2018-03-30 2019-10-03 Rheinische Friedrich-Wilhelms-Universitat Bonn Aptamers for targeted activaton of t cell-mediated immunity
KR20200141470A (en) 2018-04-06 2020-12-18 칠드런'즈 메디컬 센터 코포레이션 Composition and method for adjusting somatic cell reprogramming and imprinting
SG11202008660TA (en) 2018-04-11 2020-10-29 Ionis Pharmaceuticals Inc Modulators of ezh2 expression
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CN112189053A (en) 2018-05-09 2021-01-05 Ionis制药公司 Compounds and methods for reducing expression of ATXN3
JOP20200280A1 (en) 2018-05-09 2020-11-05 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression
TW202016304A (en) 2018-05-14 2020-05-01 美商阿尼拉製藥公司 Angiotensinogen (agt) irna compositions and methods of use thereof
WO2019241648A1 (en) 2018-06-14 2019-12-19 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing stmn2 expression
JP7315594B2 (en) 2018-06-27 2023-07-26 アイオーニス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for reducing LRRK2 expression
KR20210027389A (en) 2018-06-28 2021-03-10 크리스퍼 테라퓨틱스 아게 Compositions and methods for genome editing by insertion of donor polynucleotides
AR115847A1 (en) 2018-07-25 2021-03-03 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2
AU2019321375A1 (en) 2018-08-13 2021-03-11 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
AR115960A1 (en) 2018-08-16 2021-03-17 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE LECT2 GENE
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
JP2022500442A (en) 2018-09-14 2022-01-04 ノースウェスタン ユニバーシティ Programming of protein polymerization with DNA
CN112424355A (en) 2018-09-18 2021-02-26 阿尔尼拉姆医药品有限公司 Ketohexokinase (KHK) iRNA compositions and methods of use thereof
US20210348159A1 (en) 2018-10-17 2021-11-11 Crispr Therapeutics Ag Compositions and methods for delivering transgenes
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
CA3119456A1 (en) 2018-11-15 2020-05-22 Ionis Pharmaceuticals, Inc. Modulators of irf5 expression
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
US20210332495A1 (en) 2018-12-06 2021-10-28 Northwestern University Protein Crystal Engineering Through DNA Hybridization Interactions
SG11202106489RA (en) 2018-12-20 2021-07-29 Vir Biotechnology Inc Combination hbv therapy
CA3123617A1 (en) 2018-12-20 2020-06-25 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
JP2022517270A (en) 2019-01-16 2022-03-07 ジェンザイム・コーポレーション Serpinc1 iRNA composition and its usage
WO2020160453A1 (en) 2019-01-31 2020-08-06 Ionis Pharmaceuticals, Inc. Modulators of yap1 expression
KR20210123299A (en) 2019-02-06 2021-10-13 신톡스, 인크. IL-2 conjugates and methods of use thereof
US11529427B2 (en) 2019-02-15 2022-12-20 Crispr Therapeutics Ag Gene editing for hemophilia A with improved factor VIII expression
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
EP3927378A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
AU2020239225A1 (en) 2019-03-12 2021-09-30 Bayer Healthcare Llc Novel high fidelity RNA-programmable endonuclease systems and uses thereof
CA3134486A1 (en) 2019-03-29 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
WO2020205463A1 (en) 2019-03-29 2020-10-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats
CN113795581A (en) 2019-05-03 2021-12-14 迪克纳制药公司 Double stranded nucleic acid inhibitor molecules with shortened sense strand
US20210047649A1 (en) 2019-05-08 2021-02-18 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
US20220339256A1 (en) 2019-05-13 2022-10-27 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus (hbv) infection
BR112021025130A2 (en) 2019-06-14 2022-03-15 Scripps Research Inst Reagents and methods for replication, transcription and translation in semisynthetic organisms
US20210008161A1 (en) 2019-06-17 2021-01-14 Crispr Therapeutics Ag Methods and compositions for improved homology directed repair
EP3956450A4 (en) 2019-07-26 2022-11-16 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
WO2021022109A1 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4013870A1 (en) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
EP4013767A4 (en) 2019-08-15 2023-10-25 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds and uses thereof
CN114555128A (en) 2019-08-15 2022-05-27 新索思股份有限公司 Combination immunooncology therapy with IL-2 conjugates
BR112022003046A8 (en) 2019-08-23 2024-02-06 Synthorx Inc Il-15 conjugate, its method of preparation and its uses, as well as pharmaceutical composition and in vitro method of expanding one or more of the t cell populations
BR112022003860A2 (en) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE LECT2 GENE
US20210070827A1 (en) 2019-09-10 2021-03-11 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
EP4045652A1 (en) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (en) 2019-10-22 2022-07-12 Alnylam Pharmaceuticals Inc COMPONENTS COMPLEMENTARY C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023500661A (en) 2019-11-01 2023-01-10 アルナイラム ファーマシューティカルズ, インコーポレイテッド HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
MX2022005251A (en) 2019-11-04 2022-06-08 Synthorx Inc Interleukin 10 conjugates and uses thereof.
CN114981431A (en) 2019-11-13 2022-08-30 阿尔尼拉姆医药品有限公司 Methods and compositions for treating Angiotensinogen (AGT) -related disorders
WO2021102373A1 (en) 2019-11-22 2021-05-27 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
JP2023503635A (en) 2019-11-27 2023-01-31 クリスパー・セラピューティクス・アクチェンゲゼルシャフト Methods of synthesizing RNA molecules
CA3162717A1 (en) * 2019-11-27 2021-06-03 Alnylam Pharmaceuticals, Inc. Synthesis of 3'-rna oligonucleotides
TW202140509A (en) 2019-12-13 2021-11-01 美商阿尼拉製藥公司 Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4077674A1 (en) 2019-12-18 2022-10-26 Alia Therapeutics S.R.L. Compositions and methods for treating retinitis pigmentosa
IL294599A (en) 2020-01-15 2022-09-01 Dicerna Pharmaceuticals Inc 4’-o-methylene phosphonate nucleic acids and analogues thereof
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
TW202140786A (en) 2020-02-10 2021-11-01 美商艾爾妮蘭製藥公司 Compositions and methods for silencing vegf-a expression
MX2022010052A (en) 2020-02-18 2022-09-05 Alnylam Pharmaceuticals Inc Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof.
MX2022010602A (en) 2020-02-28 2022-09-09 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2.
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
WO2021178736A1 (en) 2020-03-06 2021-09-10 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en) 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
JP2023520582A (en) 2020-04-06 2023-05-17 アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for silencing MYOC expression
EP4133076A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
WO2021207189A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing scn9a expression
WO2021206922A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
BR112022021813A2 (en) 2020-04-27 2023-01-17 Alnylam Pharmaceuticals Inc APOLIPOPROTEIN AND (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
JP2023523790A (en) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ, インコーポレイテッド COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3181546A1 (en) 2020-05-01 2021-11-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating atxn1
EP4150090A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231691A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150088A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021237097A1 (en) 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
CN115885042A (en) 2020-05-22 2023-03-31 波涛生命科学有限公司 Double-stranded oligonucleotide compositions and methods related thereto
AR122534A1 (en) 2020-06-03 2022-09-21 Triplet Therapeutics Inc METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
JP2023530234A (en) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド Compositions and methods for treating neoplasms
WO2021252557A1 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
CA3184289A1 (en) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
BR112022026316A2 (en) 2020-06-24 2023-03-07 Vir Biotechnology Inc ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES
KR20230027235A (en) 2020-06-25 2023-02-27 신톡스, 인크. Immuno-oncology combination therapy using IL-2 conjugates and anti-EGFR antibodies
MX2022016338A (en) 2020-06-29 2023-01-24 Ionis Pharmaceuticals Inc Compounds and methods for modulating plp1.
KR20230061389A (en) 2020-08-04 2023-05-08 다이서나 파마수이티컬, 인크. Systemic Delivery of Oligonucleotides
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
WO2022070107A1 (en) 2020-09-30 2022-04-07 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis
EP4225917A1 (en) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (en) 2020-10-05 2022-04-06 SQY Therapeutics Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
AU2021356610A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
JP2023546009A (en) 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Immuno-oncology combination therapy with IL-2 conjugate and pembrolizumab
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
WO2022087041A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
TW202237841A (en) 2020-11-13 2022-10-01 美商艾拉倫製藥股份有限公司 Coagulation factor v (f5) irna compositions and methods of use thereof
EP4136092A4 (en) 2020-11-18 2023-10-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
CA3202708A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
TW202237150A (en) 2020-12-01 2022-10-01 美商艾拉倫製藥股份有限公司 Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508714A (en) 2021-02-12 2024-02-28 アルナイラム ファーマシューティカルズ, インコーポレイテッド Superoxide dismutase 1 (SOD1) iRNA composition and method for using the same for treating or preventing superoxide dismutase 1- (SOD1-) related neurodegenerative diseases
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (en) 2021-02-12 2022-12-01 美商欣爍克斯公司 Skin cancer combination therapy with il-2 conjugates and cemiplimab
CN117222739A (en) 2021-02-25 2023-12-12 阿尔尼拉姆医药品有限公司 Prion protein (PRNP) IRNA compositions and methods of use thereof
TW202302847A (en) 2021-02-26 2023-01-16 美商艾拉倫製藥股份有限公司 Ketohexokinase (khk) irna compositions and methods of use thereof
IL305414A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4304640A1 (en) 2021-03-12 2024-01-17 Northwestern University Antiviral vaccines using spherical nucleic acids
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
WO2022212231A2 (en) 2021-03-29 2022-10-06 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
WO2022212153A1 (en) 2021-04-01 2022-10-06 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022231999A1 (en) 2021-04-26 2022-11-03 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4330396A1 (en) 2021-04-29 2024-03-06 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4334448A1 (en) 2021-05-03 2024-03-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022245583A1 (en) 2021-05-18 2022-11-24 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
WO2022246023A1 (en) 2021-05-20 2022-11-24 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
TW202317762A (en) 2021-06-02 2023-05-01 美商艾拉倫製藥股份有限公司 Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2022256534A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2022256290A2 (en) 2021-06-04 2022-12-08 Alnylam Pharmaceuticals, Inc. HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
CA3222950A1 (en) 2021-06-11 2022-12-15 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
AU2022293556A1 (en) 2021-06-18 2024-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
WO2023278410A1 (en) 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
CA3225469A1 (en) 2021-06-30 2023-01-05 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023285431A1 (en) 2021-07-12 2023-01-19 Alia Therapeutics Srl Compositions and methods for allele specific treatment of retinitis pigmentosa
TW202333748A (en) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
TW202325312A (en) 2021-07-23 2023-07-01 美商艾拉倫製藥股份有限公司 Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
IL310244A (en) 2021-08-03 2024-03-01 Alnylam Pharmaceuticals Inc Transthyretin (ttr) irna compositions and methods of use thereof
IL310295A (en) 2021-08-04 2024-03-01 Alnylam Pharmaceuticals Inc iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
IL310407A (en) 2021-08-13 2024-03-01 Alnylam Pharmaceuticals Inc Factor xii (f12) irna compositions and methods of use thereof
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023069603A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202333749A (en) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 Complement factor b (cfb) irna compositions and methods of use thereof
WO2023118349A1 (en) 2021-12-21 2023-06-29 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023177866A1 (en) 2022-03-18 2023-09-21 Dicerna Pharmaceuticals, Inc. Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
WO2023194359A1 (en) 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2002773B (en) * 1977-08-10 1982-03-03 Brown R Nucleotide inhibitor of protein synthesis
US4210746A (en) * 1978-08-10 1980-07-01 National Research Development Corporation Nucleotide inhibitor of protein synthesis
US4464359A (en) * 1981-04-10 1984-08-07 Research Corporation (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
US4515781A (en) * 1983-02-23 1985-05-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 2',5'-Riboadenylate-morpholinoadenylate nucleotides
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
FR2567892B1 (en) * 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5866787A (en) * 1993-03-08 1999-02-02 Cleveland Clinic Foundation Transgenic plants co-expressing a functional human 2-5A system

Also Published As

Publication number Publication date
JPH04500795A (en) 1992-02-13
ATE135579T1 (en) 1996-04-15
DE3856326D1 (en) 1999-05-20
US4924624A (en) 1990-05-15
WO1989003683A1 (en) 1989-05-05
EP0389521B1 (en) 1996-03-20
EP0389521A1 (en) 1990-10-03
DE3855135D1 (en) 1996-04-25
EP0694559A3 (en) 1996-07-31
US5556840A (en) 1996-09-17
EP0694559B1 (en) 1999-04-14
AU2628088A (en) 1989-05-23
US5405939A (en) 1995-04-11
DE3855135T2 (en) 1996-09-05
DE3856326T2 (en) 1999-12-02
EP0694559A2 (en) 1996-01-31
ATE178902T1 (en) 1999-04-15
EP0389521A4 (en) 1992-02-05
JP2733777B2 (en) 1998-03-30

Similar Documents

Publication Publication Date Title
CA1339953C (en) 2&#39;,5&#39;-phosphorothioate oligoadenylates and antiviral uses thereof
US5188897A (en) Encapsulated 2&#39;,5&#39;-phosphorothioate oligoadenylates
US5550111A (en) Dual action 2&#39;,5&#39;-oligoadenylate antiviral derivatives and uses thereof
US5643889A (en) Cholesterol conjugates of 2&#39;5&#39;-oligoadenylate derivatives and antiviral uses thereof
US4990498A (en) 2- and 8-azido(2&#39;-5&#39;)oligoadenylates and antiviral uses thereof
US4859768A (en) Derivatives of 2&#39;, 5&#39;-oligoadenylate and antiviral uses thereof
US6033909A (en) Oligonucleotide analogs, their preparation and use
US5700785A (en) 3&#39;-deoxy or 3&#39;-O-substituted-2&#39;,5&#39;-oligoadenylates as antiviral agents
US5863905A (en) 2&#39;,5&#39;-phosphorothioate/phosphodiester oligoadenylates and anti-viral uses thereof
WO1998056385A1 (en) Base-modified derivatives of 2&#39;,5&#39;-oligoadenylate and antiviral uses thereof
AU637975B2 (en) Therapeutic uses of 2&#39;,5&#39;-oligoadenylate derivatives
CA2130926C (en) Dual action 2&#39;,5&#39;-oligoadenylate antiviral derivatives and uses thereof
IL106709A (en) Antiviral pharmaceutical compositions containing 2&#39;,5&#39;-oligoadenylates

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20130715